<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001282" GROUP_ID="AIRWAYS" ID="048799100109413531" MERGED_FROM="" MODIFIED="2011-07-26 19:06:48 +0200" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;br&gt;Short title (no longer in use): Effect of Inhaled Steroids on Growth in Children&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-07-08 09:23:20 +0100" NOTES_MODIFIED_BY="Emma J Welsh" REVIEW_NO="BEC-AST" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="5.0">
<COVER_SHEET MODIFIED="2011-07-26 19:06:48 +0200" MODIFIED_BY="Emma Welsh">
<TITLE>Beclomethasone for asthma in children: effects on linear growth</TITLE>
<CONTACT MODIFIED="2011-07-26 19:06:48 +0200" MODIFIED_BY="Emma Welsh"><PERSON ID="8605" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Sharek</LAST_NAME><EMAIL_1>psharek@leland.stanford.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Stanford University</ORGANISATION><CITY>Stanford</CITY><ZIP>94131</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-07-26 19:06:48 +0200" MODIFIED_BY="Emma Welsh"><PERSON ID="8605" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Paul</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Sharek</LAST_NAME><EMAIL_1>psharek@leland.stanford.edu</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>Stanford University</ORGANISATION><CITY>Stanford</CITY><ZIP>94131</ZIP><REGION>California</REGION><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="19393" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>David</FIRST_NAME><LAST_NAME>Bergman</LAST_NAME><POSITION>MD</POSITION><EMAIL_1>daberg@leland.stanford.edu</EMAIL_1><ADDRESS><DEPARTMENT>Division Of General Pediatrics</DEPARTMENT><ORGANISATION>Suite 100</ORGANISATION><ADDRESS_1>770 Welch Road</ADDRESS_1><CITY>Palo Alto</CITY><ZIP>CA 94305</ZIP><COUNTRY CODE="US">USA</COUNTRY></ADDRESS></PERSON><PERSON ID="5253" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Francine</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Ducharme</LAST_NAME><POSITION>Associate Director of Clinical Research (Pediatrics)</POSITION><EMAIL_1>francine.m.ducharme@umontreal.ca</EMAIL_1><ADDRESS><DEPARTMENT>Research Centre, CHU Sainte-Justine and the Department of Pediatrics</DEPARTMENT><ORGANISATION>University of Montreal</ORGANISATION><ADDRESS_1>Room number 7939</ADDRESS_1><ADDRESS_2>3175 Cote Sainte-Catherine</ADDRESS_2><CITY>Montreal</CITY><ZIP>H3T 1C5</ZIP><REGION>Québec</REGION><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>+1 514 345 4931 ext: 4398</PHONE_1><PHONE_2>+1 514 345 4931 ext: 7171</PHONE_2><FAX_1>+1 514 345 4822</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-07-21 13:52:28 +0100" MODIFIED_BY="Toby Lasserson">
<UP_TO_DATE>
<DATE DAY="3" MONTH="3" YEAR="1999"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="3" YEAR="1999"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="3" YEAR="2001"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2011-07-08 09:23:01 +0100" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-07-08 09:23:01 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="8" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Reference amended in feedback.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-07-08 09:22:13 +0100" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-07-08 09:22:06 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="25" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback incorporated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2011-07-08 09:22:10 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="25" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>The review is out of date and is being replaced with three protocols evaluating the effect of steroids in growth in children.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="FEEDBACK" MODIFIED="2011-07-08 09:22:13 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="25" MONTH="5" YEAR="2011"/>
<DESCRIPTION>
<P>Feedback has been added to the review. The review has not been amended in light of the feedback since it is no longer being updated. The unabridged version of the feedback has been sent to the authors of the new protocols.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-05-25 16:13:09 +0100" MODIFIED_BY="Emma J Welsh">
<DATE DAY="21" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="3" MONTH="3" YEAR="1999"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-07-08 09:23:20 +0100" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2008-07-21 13:44:51 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-21 13:44:51 +0100" MODIFIED_BY="Toby J Lasserson">The effect of beclomethasone on height in children</TITLE>
<SUMMARY_BODY>
<P>During an asthma attack, the airways (passages to the lungs) narrow from swelling (inflammation) and muscle spasm. This causes breathing problems, wheezing and coughing. Inhaled steroids are used to reduce the swelling to the airways, but they may also stunt growth in children. The review of trials found that the inhaled steroid, beclomethasone causes an average decrease in growth of about one and a half centimetres a year. However, it is not known whether there is any catch-up growth once the treatment is stopped. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Inhaled steroids play a central role in the management of childhood asthma. There is concern about their side effects, especially on growth. However asthma may also cause growth retardation. Growth rates are not stable, so randomised controlled parallel group studies are needed to assess the impact of inhaled steroids on growth. This review is confined to one inhaled steroid, beclomethasone, that is known to have significant levels of systemic absorption.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine whether inhaled beclomethasone cause significant delay in the linear growth of children with asthma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>The Cochrane Airways Group asthma register was searched. Bibliographies from included studies, and known reviews were searched for additional citations. Personal contact with colleagues and researchers working in the field of asthma were made to identify potentially relevant trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomized, controlled trials comparing the effects of beclomethasone to non-steroidal medication (placebo or non-steroidal therapy) on the linear growth of children with asthma.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data related to the clinical outcome "change in growth" were extracted by two reviewers working independently</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>One hundred and fifty-nine citations were identified by the search strategy and bibliography review. Three studies met the inclusion criteria. All used beclomethasone 200 mcg twice daily delivered by dry powder Diskhaler to treat children with mild-moderate asthma. Study duration was 7-12 months. In all three studies, a significant decrease in linear growth occurred in children treated with beclomethasone compared to those receiving placebo or non-steroidal asthma therapy. The average decrease, calculated through meta-analysis, was -1.54 cm per year (95% CI -1.15, -1.94). </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>In children with mild-moderate asthma, beclomethasone 200 mcg twice daily caused a decrease in linear growth of -1.54 cm per year. These studies lasted a maximum of 54 weeks, so it remains unclear whether the decrease in growth is sustained or whether it reverses with 'catch up' after therapy is discontinued. We are unable to comment on growth effects of other inhaled steroids that have potentially less systemic effects. If inhaled steroids are required to control a child's asthma, we recommend using the minimum dose that effectively controls the child's asthma and closely following growth.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-07-08 09:23:20 +0100" MODIFIED_BY="Emma J Welsh">
<BACKGROUND MODIFIED="2011-07-08 09:23:20 +0100" MODIFIED_BY="Emma J Welsh">
<P>The important role of the inflammatory process in the etiology of asthma is clearly recognized in recent consensus statements from the National Heart, Lung and Blood Institute of the National Institutes of Health (USA), the British Thoracic Society, Japanese Society of Allergy, Canadian Thoracic Society, South African Pulmonology Society, and the Thoracic Society of Australia and New Zealand (<LINK REF="REF-Nat-Inst-Health-1997" TYPE="REFERENCE">Nat Inst Health 1997</LINK>, <LINK REF="REF-British-Thor-Soc1993" TYPE="REFERENCE">British Thor Soc1993</LINK>, <LINK REF="REF-Japan-Soc-All-1995" TYPE="REFERENCE">Japan Soc All 1995</LINK>, <LINK REF="REF-Beveridge-1996" TYPE="REFERENCE">Beveridge 1996</LINK>, <LINK REF="REF-S-African-Pulm-1992" TYPE="REFERENCE">S African Pulm 1992</LINK>, Woolcock 1993). This belief is based in part on studies revealing significant improvement in asthma outcomes when patients were treated with inhaled or systemic steroids (<LINK REF="REF-Barnes-1993" TYPE="REFERENCE">Barnes 1993</LINK>, <LINK REF="REF-Dahl-1993" TYPE="REFERENCE">Dahl 1993</LINK>, <LINK REF="REF-Fabbri-1993" TYPE="REFERENCE">Fabbri 1993</LINK>, <LINK REF="REF-Gustafsson-1993" TYPE="REFERENCE">Gustafsson 1993</LINK>, <LINK REF="STD-Haahtela-1991" TYPE="STUDY">Haahtela 1991</LINK>, <LINK REF="REF-Jeffery-1992" TYPE="REFERENCE">Jeffery 1992</LINK>, <LINK REF="REF-Raffery-1985" TYPE="REFERENCE">Raffery 1985</LINK>, <LINK REF="REF-V-Essen_x002d_Zand-1992" TYPE="REFERENCE">V Essen-Zand 1992</LINK>). Inhaled corticosteroids are now felt to be the most effective long-term maintenance therapy available for mild, moderate, or severe persistent asthma. As a result they are recommended for all children with moderate or severe asthma and are recommended for consideration in children with mild persistent asthma as well.</P>
<P>As with all therapeutic interventions, there are benefits and risks to the use of inhaled steroids in children with asthma. Benefits include the substantial improvement in all measurable asthma outcomes in children treated with inhaled steroids. Risks, though less well studied, may include altered hypothalamic-pituitary axis functioning (<LINK REF="REF-Boorsma-1996" TYPE="REFERENCE">Boorsma 1996</LINK>, <LINK REF="REF-Brown-1993" TYPE="REFERENCE">Brown 1993</LINK>, <LINK REF="STD-Clark-1996" TYPE="STUDY">Clark 1996</LINK>, <LINK REF="REF-Prahl-1991" TYPE="REFERENCE">Prahl 1991</LINK>, <LINK REF="REF-Tabachnik-1991" TYPE="REFERENCE">Tabachnik 1991</LINK>) and delayed linear growth (<LINK REF="STD-Tinkelman-1993" TYPE="STUDY">Tinkelman 1993</LINK>, <LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="REF-Allen-1994" TYPE="REFERENCE">Allen 1994</LINK>. The recent requirement by the Food and Drug Administration of the U.S. Department of Health and Human Services to require labelling on all inhaled and intranasal corticosteroids warning of a possible reduction in linear growth in children well depicts this concern (FDA 1998). Attempts to determine the effect of inhaled steroids on linear growth in children with asthma are confounded by the facts that children with poorly controlled asthma tend to be growth delayed, have longer periods of reduced growth rates prior to puberty, reach puberty later than non asthmatics, and often require intermittent systemic steroids which are known to cause growth delay (<LINK REF="REF-Allen-1996" TYPE="REFERENCE">Allen 1996</LINK>, <LINK REF="REF-Balfour_x002d_Lynn-1986" TYPE="REFERENCE">Balfour-Lynn 1986</LINK>, <LINK REF="REF-Kamada-1995" TYPE="REFERENCE">Kamada 1995</LINK>). The one previous attempt to systematically evaluate the literature describing the effect of inhaled steroids on the linear growth of children with asthma, a meta-analysis by Allen (<LINK REF="REF-Allen-1994" TYPE="REFERENCE">Allen 1994</LINK>), had several flaws. In addition, several studies of high methodological quality released since this meta-analysis conflict with its conclusions (<LINK REF="STD-Tinkelman-1993" TYPE="STUDY">Tinkelman 1993</LINK>, <LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>).</P>
<P>In summary, the existence of multiple studies with conflicting results, weaknesses of the only published meta-analysis, and the persistent uncertainty in both clinical and research sectors as to whether any or all inhaled steroids cause significant linear growth delay in children with asthma, led us to undertake this systematic review.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether steroids delivered by nebulizer, metered-dose inhaler (MDI), diskhaler, rotahaler, or turbuhaler cause significant delay in the linear growth of children with asthma</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-07-21 13:49:33 +0100" MODIFIED_BY="Toby J Lasserson">
<SELECTION_CRITERIA MODIFIED="2008-07-21 13:45:18 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_STUDIES>
<P>To be included in the review, studies had to be randomized, single or double-blind, controlled trials comparing the use of beclomethasone with either placebo or non-steroidal medication in children with asthma.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Children (&lt;18 years old at entry into the study) with the diagnosis of asthma, who have been off inhaled and oral steroids for a minimum of 3 months prior to the study.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Patients must have been participants in studies that utilize randomization to assign beclomethasone, or a non steroidal medication (control). The inhaled steroid must have been delivered by a nebulizer, metered-dose inhaler, diskhaler, or rotahaler for a minimum of 3 months. All doses were accepted, and were classified into the categories of 'low', 'medium', or 'high' as defined by the United States NHLBI guidelines (<LINK REF="REF-Nat-Inst-Health-1997" TYPE="REFERENCE">Nat Inst Health 1997</LINK>)</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-07-21 13:45:18 +0100" MODIFIED_BY="Toby J Lasserson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-07-21 13:45:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The primary outcome measure was linear growth velocity. All studies including outcomes that could be converted to linear growth velocity were considered.</P>
</CRIT_OUTCOMES_PRIMARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-07-21 13:46:16 +0100" MODIFIED_BY="Toby J Lasserson">
<ELECTRONIC_SEARCHES MODIFIED="2008-07-21 13:46:16 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The Cochrane Airways Group asthma register was searched using the following terms:</P>
<P>((steroid* OR corticosteroid* OR glucocorticoid* OR beclomethasone) AND (inhale*)) AND (child* OR infan* OR adolescen* OR pediatr* OR paediatr*)</P>
<P>Each abstract was reviewed and annotated as: randomized controlled trial (RCT), clearly not an RCT or unclear. Only publications annotated as clearly not an RCT were removed at that stage.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-07-21 13:45:45 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Each remaining abstract from the search results was reviewed to determine if it met the inclusion criteria. Trials with citations having relevant titles not displaying abstracts were reviewed to determine eligibility, as were all trials not specifically removed for failure to meet the inclusion criteria based on title or abstract. Reference lists of all identified RCTs were checked to identify potentially relevant citations. Personal contact was made with colleagues and researchers working in the field of asthma to identify potentially relevant trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-07-21 13:49:33 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_SELECTION MODIFIED="2008-07-21 13:46:35 +0100" MODIFIED_BY="Toby J Lasserson">
<P>From the title, abstract, or descriptors, two reviewers (PS and DB) independently reviewed literature searches, bibliographies, and texts to identify potentially relevant trials for full review. From the full text, two reviewers (PS and DB) independently selected trials for inclusion into this review based on the inclusion criteria. Agreement was measured using Kappa statistics, and disagreement was resolved by consensus.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-07-21 13:46:48 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Data for the trials were extracted by two reviewers (PS and DB). Primary study authors were contacted to provide additional clarification and information for the review if necessary. Confirmation of methodology and data was obtained in one study (<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>). A second study (<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>) required an estimate of standard deviations from other data presented in the paper as the authors could not be contacted.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-07-21 13:48:12 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Methodologic quality assessment: Each reviewer independently assessed the methodological quality of the included trials and ranked them using the Cochrane approach to quality assessment (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>) based on allocation concealment (randomization) as follows:</P>
<P>Grade A: Adequate allocation concealment<BR/>Grade B: Uncertain<BR/>Grade C: Clearly inadequate allocation concealment</P>
<P>Inter-rater reliability was measured by using simple agreement and kappa weighted statistics. Where there was uncertainty, authors were contacted to clarify the allocation concealment (randomization) method used.</P>
<P>In addition, each author independently assigned a quality score based on the methodology of Jadad (Jadad, 1996) to each included study. With this methodology, each study included is assessed using a 0-5 scale as summarized below:</P>
<P>1. Was the study described as randomized (1=yes; 0=no)?<BR/>2. Was the study described as double blind (1=yes; 0=no)?<BR/>3. Was there a description of withdrawals and dropouts (1=yes; 0=no)?<BR/>4. Was the method of randomization well described and appropriate (1=yes; 0=no)?<BR/>5. Was the method of double-blinding well described and appropriate (1=yes; 0=no)?<BR/>6. Deduct 1 point if methods for randomization or blinding were inappropriate.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-07-21 13:47:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Linear growth velocity was analysed as a continuous variable, so individual and pooled statistics were calculated as weighted mean differences (WMD) and 95% confidence intervals. A fixed effects model was used</P>
</EFFECT_MEASURES>
<DATA_SYNTHESIS MODIFIED="2008-07-21 13:49:33 +0100" MODIFIED_BY="Toby J Lasserson">
<P>For analysis, data were entered into RevMan to ensure that the Cochrane convention was followed: i.e. that differences between treatments that favoured control went to the left, and those favouring treatment went to the right. In this review, the outcome (growth velocity) was reduced (unfavourably) by the treatment - thus favouring control.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-07-21 13:47:18 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Subgroup analysis was planned a priori to compare the effect on linear growth of specific strengths of inhaled steroid used (low, medium, or high).</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-07-21 13:47:29 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Six specific sensitivity analyses were planned a priori. These analyses were planned to evaluate the role of each of the following in the final statistical summary:</P>
<P>1. The random effects compared to fixed effects model</P>
<P>2. High methodologic compared to low methodologic quality studies</P>
<P>3. Published compared to unpublished data (publication bias)</P>
<P>4. Duration of intervention (less than six months compared to greater than six months)</P>
<P>5. Age of subjects (less than 13 years of age compared to greater than 13 years of age)</P>
<P>6. Method of delivery of inhaled steroid (nebulizer compared to metered-dose inhaler compared to rotahaler compared to turbuhaler compared to diskhaler)</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-07-21 13:49:56 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDY_DESCRIPTION MODIFIED="2008-07-21 13:49:01 +0100" MODIFIED_BY="Toby J Lasserson">
<SEARCH_RESULTS MODIFIED="2008-07-21 13:48:49 +0100" MODIFIED_BY="Toby J Lasserson">
<P>A total of 159 citations were identified using both the search strategy described above and bibliography review. The search strategy identified 93 citations, and the bibliography review identified 66 additional citations. Sixty-seven citations were eliminated by review of the title or abstract with the remaining 92 citations being reviewed with full text. Of these 92 remaining citations, 3 studies satisfied all eligibility requirements for inclusion and 89 studies did not. Reasons for study exclusion included: improper study design (n=113), improper population (n=19), improper outcome measure (n=9), improper intervention (n=8), improper control group (n=3), and the study used a subset of a larger population published in total elsewhere (n=4). Substantial inter rater agreement (K score, 0.98) for trial inclusion into the meta-analysis for the studies not excluded by title or abstract was attained (<LINK REF="REF-Last-1995" TYPE="REFERENCE">Last 1995</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2008-07-21 13:49:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Only three studies met the inclusion criteria: <LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, and <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>. All of these studies used the inhaled steroid beclomethasone.</P>
<P>Design: Each of the included studies was a randomized controlled clinical trial. Each was double blind (subject and provider) to treatment assignment.</P>
<P>Populations: Although all studies required study patients to have asthma, they differed substantially on their definitions. Two studies [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] used pulmonary function test requirements for inclusion, while the third study [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] did not. One study (<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>) required a minimum symptom burden while the other two [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] did not. Each study selected a population of patients thought to have clinically stable asthma at the time of enrolment, and each selected a population consistent with the mild to moderate category of asthma as defined by the NIH guidelines (<LINK REF="REF-Nat-Inst-Health-1997" TYPE="REFERENCE">Nat Inst Health 1997</LINK>). Each study enrolled only patients that had been off of inhaled or systemic steroids for a minimum of 3 months (<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>: never used steroids; <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>: no steroids for at least 6 months; <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>: no steroids for at least 3 months and sum total of steroids was less than 1 month). Drop out rates varied widely between studies (Doull 10.6%; Verberne 16.1%; Simons 25.3%)</P>
<P>Interventions: Each of the three studies used beclomethasone. Two of the three [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] used a diskhaler device for delivery while the third [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used a metered-dose inhaler. Two of the three [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] used a placebo control while the third [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] used Salmeterol as the control medication. The dose of beclomethasone was consistent between all three studies at 200 mcg twice daily which is classified as medium dose by National Asthma Education and Prevention Program Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma (<LINK REF="REF-Nat-Inst-Health-1997" TYPE="REFERENCE">Nat Inst Health 1997</LINK>). The duration of treatment varied from 7 months [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] to 54 weeks <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>]. Compliance was estimated in two of the studies [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] ranging from 75% to 92%.</P>
<P>Outcome: All three studies reported changes in height for the duration of the treatment, and calculated growth velocity using the regression coefficient of height on time. One study [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] did not report the standard deviations for the linear growth velocities of each group and attempts to obtain this information from the author were unsuccessful. From data provided in the text, standard deviations were estimated using the assumption that the standard deviation of intervention and control groups was equal. This is a reasonable assumption that does not significantly alter the results of the meta-analysis. Two of the three studies [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] used a stadiometer to measure height while the third study [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used a minimeter. Only one of the three trials [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used growth as the primary outcome. In the other two [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] growth was recorded as a secondary outcome measure.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-07-21 13:48:01 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Randomization: All included studies allocated treatment by randomization. Two studies used an independent randomization center [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>]. The third study [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>] does not discuss how randomization was accomplished and attempts to contact the authors were unsuccessful.</P>
<P>Blinding of treatment and outcome assessment: All studies are described as double-blind. The measurer of height was blind to the treatment group in one study [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>], but measurer blindedness is not stated in the other two studies [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>].</P>
<P>Exclusion after randomization: Drop out rates varied from 10.6% [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] to 16.1% [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] to 25.3% [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>]. Each study adequately addressed the reasons for drop out. In order of frequency these included: severe asthma exacerbation during the study, adverse events, noncompliance with the protocol, control patients initiating inhaled steroids, back injury affecting growth, and "other". Only one study [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used an intention to treat analysis which revealed similar conclusions when the dropouts were included or excluded in the analysis.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-07-21 13:49:56 +0100" MODIFIED_BY="Toby J Lasserson">
<P>The weighted-mean difference from the meta-analysis was -1.54 cm per year (95% confidence interval -1.15, -1.94). This corresponds to a reduction in growth velocity of approximately 25%.</P>
<P>Subgroup analysis comparing the effects of different dosing levels of inhaled steroids (low, medium, or high) was not possible since beclomethasone was used in 200 mcg twice daily was used in all three studies.</P>
<P>Sensitivity analysis of the affects of the statistical model (random effects vs. fixed effects), methodological quality, publication bias, duration of intervention (less than 6 months versus greater than 6 months), age of subjects (less than 13 years old versus greater than 13 years old), and method of delivery of inhaled steroid (nebulizer versus MDI versus rotahaler versus turbuhaler versus diskhaler) were performed. The results are summarized below.</P>
<P>Random vs. fixed effect model: Use of the random effects model with our included studies reveals a weighted mean difference of -1.51 cm/year and a confidence interval of (-1.03, -1.99). This outcome is consistent with that of the fixed effect model which calculates a weighted mean difference of -1.54 cm per year and confidence interval of -1.15 cm per year to -1.94 cm per year.</P>
<P>Methodologic Quality: Quality scores were calculated using two separate formulas. Assessment based on allocation concealment (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>) revealed two studies with grade A [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] and one study with grade B [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>]. Assessment, based on the method of Jadad (Jadad 1996), resulted in a grade of 5 for one study [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>], grade 4 for one study [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] and grade of 3 for the third [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>]. Each study was evaluated independently for quality by the two authors, with Kappa scores of 1.0 for allocation concealment and 1.0 for the method of Jadad. Removal of all studies of lower quality (less than grade A concealment allocation) resulted in a weighted mean difference of -1.73 cm per year (95% CI -1.27,-2.20). Similarly, removal of all studies of lower quality with Jadad score less than 4 again resulted in a weighted mean difference of -1.73 cm/year (95% CI -1.27 to -2.20).</P>
<P>Publication Bias: A funnel plot showed no evidence of publication bias.</P>
<P>Length of treatment: Since none of the studies included was less than 6 months duration, no sensitivity analysis could be performed based on this criterion.</P>
<P>Age of subjects: Sensitivity analysis of subjects based on age (below or above 13 years old) could not be performed due to an inability to accurately group patients by age. Authors were unable to provide individual data stratified by age.</P>
<P>Mode of medication delivery: Since all three studies [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>, <LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used diskhalers, no sensitivity analysis could be performed on this criterion</P>
<P>There was no heterogeneity between studies; chi square was 2.71 with 2 degrees of freedom &gt;.99.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Three studies evaluating the effect of inhaled steroids on the linear growth of children with asthma met our inclusion criteria. Although each population had mild to moderate asthma severity, important differences in study interventions and populations existed that might have influenced the results of this analysis. First, the duration of steroid therapy varied between studies with a minimum of 7 months [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] to a maximum of 54 weeks [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>]. Second, the inclusion criteria for subjects differed between studies. No attempts were made in any of these studies to classify patient severity based on the internationally recognized guidelines. Only two of the studies [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] incorporated pulmonary function test parameters into the inclusion criteria. Each study used a different baseline between the last use of inhaled steroid allowed and enrolment (from "three months" before the study to "never allowed"). Third, the total number of analysed patients varied from 67 [<LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] to 241 [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>]. Finally, drop out rates varied between studies, from 10.6% [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] to 25.3 % [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>]. The impact of all of these differences is unknown, however the similar effect sizes and absence of heterogeneity suggest that their impact was small.</P>
<P>The meta-analysis shows a statistically significant decrease in linear growth velocity of children with mild to moderate asthma treated with moderate doses of beclomethasone. This is the opposite conclusion that reached by Allen et al in their meta-analysis of observational studies (<LINK REF="REF-Allen-1994" TYPE="REFERENCE">Allen 1994</LINK>). Several reasons for this discrepancy are plausible. First, to minimize selection bias we only used randomized controlled trials whereas Allen et al used only cohort studies. Second, to promote equivalent control and study populations, the control population groups in the studies included in this review only contained children with asthma whereas Allen et al allowed control populations of children without asthma. Third, we used an extensive search strategy to minimize study selection bias whereas Allen et al did not state their search strategy. Fourth, we included studies that either measured growth velocity directly or had outcomes that could be converted to growth velocity. In contrast, Allen et al excluded all studies using growth velocity or summary statistics in the outcome. Fifth, we graded the quality of each included study and performed sensitivity analysis to determine the effect of study quality on the outcome measure, whereas Allen et al did not. Sixth, although not an a priori exclusion criterion, all studies included in our analysis had loss to follow up at 25% or less whereas Allen et al included studies with much larger loss to follow-up. Seventh, we evaluated the effects of publication bias on the overall conclusions of the meta-analysis whereas Allen et al did not. Finally we tested the of heterogeneity of the effect sizes between studies, whereas Allen et al did not statistically determine the possibility of significantly heterogeneous study populations. Overall, we conclude that methodologic rigor of our analysis increased the reliability of our findings and the conclusions to be drawn from them.</P>
<P>A review of the Hill criteria for causal inference (<LINK REF="REF-Hill-1965" TYPE="REFERENCE">Hill 1965</LINK>), strengthens our conclusion that 200 mcg twice of beclomethasone causes decreased linear growth in children with mild to moderate asthma. First, the quality of the included trials was high, since all were all randomized controlled clinical trials that passed a set of a priori inclusion criteria. Second, the size of the measure of effect is large and of clinical significance. Third, the effect of inhaled steroids on linear growth is consistent across all three trials, despite a variety of ages, ethnicity, and treatment duration. Fourth, there is substantial indirect evidence that supports the likelihood that inhaled steroids effect linear growth. Studies evaluating inhaled steroids have shown decreased bone formation in adults (<LINK REF="REF-Ali-1991" TYPE="REFERENCE">Ali 1991</LINK>, <LINK REF="STD-Toogood-1991" TYPE="STUDY">Toogood 1991</LINK>, <LINK REF="REF-Pouw-1991" TYPE="REFERENCE">Pouw 1991</LINK>, <LINK REF="REF-Packe-1992" TYPE="REFERENCE">Packe 1992</LINK>), systemic steroids are well-known to cause significant growth delay (<LINK REF="REF-Allen-1996" TYPE="REFERENCE">Allen 1996</LINK>, <LINK REF="REF-Balfour_x002d_Lynn-1986" TYPE="REFERENCE">Balfour-Lynn 1986</LINK>, <LINK REF="REF-Kamada-1995" TYPE="REFERENCE">Kamada 1995</LINK>), inhaled steroids have been shown to depress the hypothalamic-pituitary axis revealing significant systemic absorption (<LINK REF="REF-Boorsma-1996" TYPE="REFERENCE">Boorsma 1996</LINK>, <LINK REF="REF-Brown-1993" TYPE="REFERENCE">Brown 1993</LINK>, <LINK REF="STD-Clark-1996" TYPE="STUDY">Clark 1996</LINK>, <LINK REF="REF-Prahl-1991" TYPE="REFERENCE">Prahl 1991</LINK>, <LINK REF="REF-Tabachnik-1991" TYPE="REFERENCE">Tabachnik 1991</LINK>), and recent data suggests nasal steroids may effect growth velocity (<LINK REF="REF-FDA-1998" TYPE="REFERENCE">FDA 1998</LINK>). Fifth, plausible alternative explanations of the observed effects, including selection bias and publication bias, have been minimized or eliminated by the methodology of this review. The sixth and final criterion for causal inference, that of a dose-response relationship between inhaled steroids and linear growth delay could not be evaluated because all studies used the same dose of drug.</P>
<P>We could not carry out sensitivity analysis of subjects based on age (below or above 13 years old). Two of the studies, [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] included patients above and below age 13, but analysis within the publication was not stratified into these age groups. Authors were unable to provide individual data stratified by age. This is of interest since there is evidence that inhaled steroids may not effect linear growth in post-pubescent adolescents (<LINK REF="STD-Tinkelman-1993" TYPE="STUDY">Tinkelman 1993</LINK>).</P>
<P>The effect of removing studies utilizing different methods of medication delivery was minimal. Two studies [<LINK REF="STD-Simons-1997" TYPE="STUDY">Simons 1997</LINK>, <LINK REF="STD-Verberne-1997" TYPE="STUDY">Verberne 1997</LINK>] used Diskhalers for the delivery of treatment and control medication, while the third [<LINK REF="STD-Doull-1995" TYPE="STUDY">Doull 1995</LINK>] used metered-dose inhalers. Within the limits of the available evidence, we conclude that the mode of medication delivery does not significantly alter the effect of beclomethasone on growth. </P>
<P>Finally, we are not able to comment on the possible effects on growth of other inhaled steroids that may have lower levels of systemic activity, nor on the impact of alternative systems for the delivery of corticosteroids.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Beclomethasone 200 mcg twice daily in children with mild to moderate asthma significantly reduces linear growth velocity over 7-12 months in children with mild to moderate asthma. It is not known whether similar effects occur with other inhaled steroids such as budesonide or fluticasone that have lower systemic bio-availability. It is not known whether there is significant catchup growth if the beclomethasone is discontinued. These data suggest that inhaled steroid use be kept to the smallest dose that adequately controls the disease. It would seem prudent to use an inhaled steroid with potentially less systemic effect than beclomethasone. Regular monitoring of linear growth in children with asthma using these medications may aid treatment decisions in individual patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Research efforts should concentrate on evaluating the long-term effects of inhaled steroids, effects of other inhaled steroid medications, and the effect of different doses. If growth effects are unavoidable with maintenance treatment, dosing strategies that may permit catch up periods should be evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors acknowledge the time and expertise of Francine Ducharme MD editor and Paul Jones MD PhD co-editor, and the Airways Review Group of the Cochrane Collaboration. In addition, we acknowledge the financial assistance of the Lucile and David Packard Foundation.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>Neither of the two authors has any affiliations that might place us in a conflict of interest situation. Neither of the two authors has been involved in an included or excluded trial as Principal Investigator, Steering or Monitoring Committee member, Co-Investigator or Site Coordinator. Francine Ducharme MD editor, has received some travel support for meeting attendance, research grant and consulting fees from Glaxo-Dminth Kline Inc.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>PS: Protocol initiation and development, assessed search results, data extraction, entry and analysis, interpretation and write-up<BR/>DB: Protocol initiation and development, assessed search results, data extraction, entry and analysis, interpretation and write-up<BR/>FD: Editorial support and guidance throughout</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Doull-1995" NAME="Doull 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doull IJ, Freezer NJ, Holgate ST</AU>
<TI>Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate [see comments]. American Journal of Respiratory and Critical Care Medicine</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>6</NO>
<PG>1715-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simons-1997" NAME="Simons 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simons FE, et al</AU>
<TI>A Comparison of Beclomethasone, Salmeterol, and Placebo in Children with Asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1997</YR>
<VL>337</VL>
<PG>1659-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verberne-1997" NAME="Verberne 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verberne AAPH, Frost C, Jan Roorda R, van der Laag H, Kerrebijn K, et al</AU>
<TI>One year Treatment with Salmeterol Compared with Beclomethasone in Children with Asthma</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1997</YR>
<VL>156</VL>
<PG>688-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Agertoft-1994" NAME="Agertoft 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Agertoft L, Pedersen S</AU>
<TI>Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<PG>373-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ahrens-1993" NAME="Ahrens 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahrens J</AU>
<TI>Risks and safety of asthma therapy</TI>
<TO>Risiken und Sicherheit der Asthmatherapie</TO>
<SO>Therapiewoche</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>50</NO>
<PG>1950-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Allen-1998" NAME="Allen 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Allen, D. B.; Bronsky, E. A.; LaForce, C. F.; Nathan, R. A.; Tinkelman, D.; Vandewalker, M. L.; Knoig, P. Growth in asthmatic children treated with fluticazone propionate. Journal of Pediatrics. 1998;132(3 I):472-477.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman D, Vandewalker ML, et al</AU>
<TI>Growth in asthmatic children treated with fluticazone propionate</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>132</VL>
<NO>3 I</NO>
<PG>472-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apold-1975" NAME="Apold 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Apold J; Djoseland O.Inhaled beclomethasone dipropionate in the treatment of childhood asthma. Postgraduate Medical Journal. 1975; 51 Suppl 4:104-5.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apold J, Djoseland O</AU>
<TI>Inhaled beclomethasone dipropionate in the treatment of childhood asthma</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1975</YR>
<VL>51 Suppl 4</VL>
<PG>104-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arkins-1968" NAME="Arkins 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Arkins JA; Schleuter DP; Fink JN. The effect of corticosteroids on methacholine inhalation in symptomatic bronchial asthma. Journal of Allergy. 1968; 41(4):209-16.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arkins JA, Schleuter DP, Fink JN</AU>
<TI>The effect of corticosteroids on methacholine inhalation in symptomatic bronchial asthma</TI>
<SO>Journal of Allergy</SO>
<YR>1968</YR>
<VL>41</VL>
<NO>4</NO>
<PG>209-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennati-1989" NAME="Bennati 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Bennati D; Piacentini GL; Peroni DG; Sette L; Testi R; Boner AL. Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol. Journal of Asthma, 1989, 26(6):359-64.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennati D, Piacentini GL, Peroni DG, Sette L, Testi R, Boner AL</AU>
<TI>Changes in bronchial reactivity in asthmatic children after treatment with beclomethasone alone or in association with salbutamol</TI>
<SO>Journal of Asthma</SO>
<YR>1989</YR>
<VL>26</VL>
<NO>6</NO>
<PG>359-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benoist-1992" NAME="Benoist 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1990" NAME="Bisgaard 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Bisgaard, H., Munck, S. L., Nielsen, J. P., Petersen, W., and Ohlsson, S. V.  Inhaled budesonide for treatment of recurrent wheezing in early childhood.   Lancet 1990; 336:649-51&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H, Munck SL, Nielsen JP, Petersen W, Ohlsson SV</AU>
<TI>Inhaled budesonide for treatment of recurrent wheezing in early childhood</TI>
<SO>Lancet</SO>
<YR>1990</YR>
<VL>336</VL>
<PG>649-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bisgaard-1993" NAME="Bisgaard 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Bisgaard, H.  Systemic activity of inhaled topical steroid in toddlers studied by knemometry.   Acta-Paediatr 1993; 82:1066-71&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bisgaard H</AU>
<TI>Systemic activity of inhaled topical steroid in toddlers studied by knemometry</TI>
<SO>Acta Paediatrica</SO>
<YR>1993</YR>
<VL>82</VL>
<PG>1066-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boner-1995" NAME="Boner 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Boner AL; Comis A; Schiassi M; Venge P; Piacentini GL.&lt;br&gt;Bronchial reactivity in asthmatic children at high and low altitude.Effect of budesonide. American Journal of Respiratory and Critical Care Medicine. 1995;151(4):1194-200.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boner AL, Comis A, Schiassi M, Venge P, Piacentini GL</AU>
<TI>Bronchial reactivity in asthmatic children at high and low altitude. Effect of budesonide</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>4</NO>
<PG>1194-200</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Booms-1997" NAME="Booms 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Booms P; Cheung D; Timmers MC; Zwinderman AH; Sterk PJ. Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma. Journal of Allergy and Clinical Immunology, 1997; 99(3):330-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Booms P, Cheung D, Timmers MC, Zwinderman AH, Sterk PJ</AU>
<TI>Protective effect of inhaled budesonide against unlimited airway narrowing to methacholine in atopic patients with asthma</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1997</YR>
<VL>99</VL>
<NO>3</NO>
<PG>330-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1996" NAME="Clark 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Clark DJ; Grove A; Cargill RI; Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996; 51(3):262-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark DJ, Grove A, Cargill RI, Lipworth BJ</AU>
<TI>Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients</TI>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>3</NO>
<PG>262-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crowley-1995" NAME="Crowley 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crowley S, Hindmarsh PC, Matthews DR, Brook CGD</AU>
<TI>Growth and the growth hormone axis in prepubertal children with asthma</TI>
<SO>Journal of Pediatrics</SO>
<YR>1995</YR>
<VL>126</VL>
<NO>2</NO>
<PG>297-303</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crowley-1998" NAME="Crowley 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crowley S, Trivedi P, Risteli L, Risteli J, Hindmarsh PC, Brook CG</AU>
<TI>Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>132</VL>
<NO>3 Pt 1</NO>
<PG>409-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Damsbo-1994" NAME="Damsbo 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Damsbo N</AU>
<TI>Budesonide in the treatment of mild asthma. A placebo-controlled multicenter study in general practice</TI>
<TO>Budesonid i behandling af mild astma. En placebokontrolleret multicenterundersogelse i almen praksis</TO>
<SO>Ugeskrift for Laeger</SO>
<YR>1994</YR>
<VL>156</VL>
<NO>43</NO>
<PG>6384-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Blic-1996" NAME="De Blic 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;de Blic J; Delacourt C; Le Bourgeois M; Mahut B; Ostinelli J; Caswell C;  Scheinmann P.  Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study.  Journal of Allergy and Clinical Immunology. 1996; 98(1):14-20.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Blic J, Delacourt C, Le Bourgeois M, Mahut B, Ostinelli J, Caswell C, et al</AU>
<TI>Efficacy of nebulized budesonide in treatment of severe infantile asthma: a double-blind study</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1996</YR>
<VL>98</VL>
<NO>1</NO>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doull-1995_x0028_2_x0029_" NAME="Doull 1995(2)" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Doull IJ; Donovan SJ; Wood PJ; Holgate ST. Bloodspot cortisol in mild asthma: the effect of inhaled corticosteroids. Archives of Disease in Childhood.1995; 72(4):321-4.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doull IJ, Donovan SJ, Wood PJ, Holgate ST</AU>
<TI>Bloodspot cortisol in mild asthma: the effect of inhaled corticosteroids</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1995</YR>
<VL>72</VL>
<NO>4</NO>
<PG>321-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doull-1996" NAME="Doull 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Doull, I., Freezer, N., and Holgate, S.  Osteocalcin, growth, and inhaled corticosteroids: a prospective study.   Arch-Dis-Child 1996; 74:497-501&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doull I, Freezer N, Holgate S</AU>
<TI>Osteocalcin, growth, and inhaled corticosteroids: a prospective study</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1996</YR>
<VL>74</VL>
<PG>497-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Doull-1997" NAME="Doull 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doull lJ, Sandall D, Smith S, Schreiber J, Freezer NJ, Holgate ST</AU>
<TI>Differential inhibitory effect of regular inhaled corticosteroid on airway responsiveness to adenosine 5' monophosphate, methacholine, and bradykinin in symptomatic children with recurrent wheeze</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>23</VL>
<NO>6</NO>
<PG>404-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Droszcz-1988" NAME="Droszcz 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Droszcz W; Piotrowska B; Madalinska M; Walajtys-Rode E; Wieniawska-Szewczyk E. Clinical results and the adrenal cortex activity in patients with bronchial asthma treated by inhalation of budesonide. Evaluation of the results after 1-year treatment. Polskie Archiwum Medycyny Wewnetrznej. 1988;80(2-3):70-5.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Droszcz W, Piotrowska B, Madalinska M, Walajtys-Rode E, Wieniawska-Szewczyk E</AU>
<TI>Clinical results and the adrenal cortex activity in patients with bronchial asthma treated by inhalation of budesonide. Evaluation of the results after 1-year treatment</TI>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>1988</YR>
<VL>80</VL>
<NO>2-3</NO>
<PG>70-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Du-toit-1986" NAME="Du toit 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;du Toit, J. I., Salome CM, and Woolcock AJ.  Short term effects of inhaled corticosteroids on bronchial hyperresponsiveness.   Australian-and-New-Zealand-Journal-of-Medicine 1986; 16:627&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>du Toit JI, Salome CM, Woolcock AJ</AU>
<TI>Short term effects of inhaled corticosteroids on bronchial hyperresponsiveness</TI>
<SO>Australian-and-New-Zealand-Journal-of-Medicine</SO>
<YR>1986</YR>
<VL>16</VL>
<PG>627</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eefthimiou-1998" NAME="Eefthimiou 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Efthimiou, J.; Barnes, P. J. Effect of inhaled corticosteroids on bones and growth. European Respiratory Journal. 1998; 11(5):1167-1177.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Efthimiou J, Barnes PJ</AU>
<TI>Effect of inhaled corticosteroids on bones and growth</TI>
<SO>European Respiratory Journal</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>5</NO>
<PG>1167-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Falliers-1982" NAME="Falliers 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Falliers CJ; Petraco AJ. Control of asthma with triamcinolone acetonide aerosol inhalations at 12-hour intervals.Journal of Asthma. 1982; 19(4):241-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Falliers CJ, Petraco AJ</AU>
<TI>Control of asthma with triamcinolone acetonide aerosol inhalations at 12-hour intervals</TI>
<SO>Journal of Asthma</SO>
<YR>1982</YR>
<VL>19</VL>
<NO>4</NO>
<PG>241-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Field-1982" NAME="Field 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Field HV; Jenkinson PM; Frame MH; Warner JO. Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler. Archives of Disease in Childhood, 1982; 57(11):864-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Field HV, Jenkinson PM, Frame MH, Warner JO</AU>
<TI>Asthma treatment with a new corticosteroid aerosol, budesonide, administered twice daily by spacer inhaler</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1982</YR>
<VL>57</VL>
<NO>11</NO>
<PG>864-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Francis-1984" NAME="Francis 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Francis RS; McEnery G. Disodium cromoglycate compared with beclomethasone dipropionate in juvenile asthma. Clinical Allergy. 1984; 14(6):537-40.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Francis RS, McEnery G</AU>
<TI>Disodium cromoglycate compared with beclomethasone dipropionate in juvenile asthma</TI>
<SO>Clinical Allergy</SO>
<YR>1984</YR>
<VL>14</VL>
<NO>6</NO>
<PG>537-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frank_x002d_Piskorska-1988" NAME="Frank-Piskorska 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Frank-Piskorska A; Wasek Z; Malinowski R; Lypka A. Long-term therapy using beclomethasone preparations in our experience. Pneumonologia Polska, 1988 Nov, 56(11):518-22.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frank-Piskorska A, Wasek Z, Malinowski R, Lypka A</AU>
<TI>Long-term therapy using beclomethasone preparations in our experience</TI>
<SO>Pneumonologia Polska</SO>
<YR>1988</YR>
<VL>56</VL>
<NO>11</NO>
<PG>518-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freezer-1995" NAME="Freezer 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Freezer NJ; Croasdell H; Doull IJ; Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. European Respiratory Journal. 1995;8(9):1488-93.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freezer NJ, Croasdell H, Doull IJ, Holgate ST</AU>
<TI>Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze</TI>
<SO>European Respiratory Journal</SO>
<YR>1995</YR>
<VL>8</VL>
<NO>9</NO>
<PG>1488-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galant-1996" NAME="Galant 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Galant SP; Lawrence M; Meltzer EO; Tomasko M; Baker KA; Kellerman DJ.  Fluticasone propionate compared with theophylline for mild-to-moderate asthma. Annals of Allergy, Asthma, and Immunology. 1996; 77(2):112-8.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galant SP, Lawrence M, Meltzer EO, Tomasko M, Baker KA, Kellerman DJ</AU>
<TI>Fluticasone propionate compared with theophylline for mild-to-moderate asthma</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>1996</YR>
<VL>77</VL>
<NO>2</NO>
<PG>112-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ggajanan-1993" NAME="Ggajanan 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Gajanan, S. G.  Inhaled corticosteroids in childhood bronchial asthma.    National Medical Journal of India 1993 Mar-Apr; 6:(2):76-7&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gajanan SG</AU>
<TI>Inhaled corticosteroids in childhood bronchial asthma</TI>
<SO>National Medical Journal of India</SO>
<YR>1993 Mar-Apr</YR>
<VL>6</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haahtela-1991" NAME="Haahtela 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Haahtela T; Jarvinen M; Kava T; Kiviranta K; Koskinen S; Lehtonen K; Nikander K; Persson T; Reinikainen K; Selroos O; et al.comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma [see comments].New England Journal of Medicine. 1991;325(6):388-92.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al</AU>
<TI>Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma [see comments]</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<NO>6</NO>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Henriksen-1985" NAME="Henriksen 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Henriksen JM. Effect of inhalation of corticosteroids on exercise induced asthma: randomised double blind crossover study of budesonide in asthmatic children. British Medical Journal (Clinical Research Ed.). 1985; 291(6490):248-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Henriksen JM</AU>
<TI>Effect of inhalation of corticosteroids on exercise induced asthma: randomised double blind crossover study of budesonide in asthmatic children</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1985</YR>
<VL>291</VL>
<NO>6490</NO>
<PG>248-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoekstra-1996" NAME="Hoekstra 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Hoekstra MO; Grol MH; Bouman K; Stijnen T; Koeter GH; Kauffman HF; Gerritsen J. Fluticasone propionate in children with moderate asthma. American Journal of Respiratory and Critical Care Medicine. 1996;154(4Pt 1):1039-44.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoekstra MO, Grol MH, Bouman K, Stijnen T, Koeter GH, Kauffman HF, et al</AU>
<TI>Fluticasone propionate in children with moderate asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>154</VL>
<NO>4Pt 1</NO>
<PG>1039-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horn-1990" NAME="Horn 1990" YEAR="1990">
<REFERENCE NOTES="&lt;p&gt;Horn CR; Clark TJ; Cochrane GM. Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study. Respiratory Medicine.1990; 84(1):61-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horn CR, Clark TJ, Cochrane GM</AU>
<TI>Can the morbidity of asthma be reduced by high dose inhaled therapy? A prospective study</TI>
<SO>Respiratory Medicine</SO>
<YR>1990</YR>
<VL>84</VL>
<NO>1</NO>
<PG>61-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ishihara-1995" NAME="Ishihara 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Ishihara K; Hasegawa T; Okazaki M; Katakami N; Sakamoto H; Umeda B; Nakai  H. Long-term follow-up of patients with a history of near fatal episodes; can inhaled corticosteroids reduce the risk of death from asthma? Internal Medicine. 1995;34(2):77-80.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ishihara K, Hasegawa T, Okazaki M, Katakami N, Sakamoto H, Umeda B, et al</AU>
<TI>Long-term follow-up of patients with a history of near fatal episodes; can inhaled corticosteroids reduce the risk of death from asthma?</TI>
<SO>Internal Medicine</SO>
<YR>1995</YR>
<VL>34</VL>
<NO>2</NO>
<PG>77-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-1994" NAME="Jones 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Jones AH; Langdon CG; Lee PS; Lingham SA; Nankani JP; Follows RM; Tollemar U; Richardson PD. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respiratory Medicine. 1994;88(4):293-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones AH, Langdon CG, Lee PS, Lingham SA, Nankani JP, Follows RM, et al</AU>
<TI>Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma</TI>
<SO>Respiratory Medicine</SO>
<YR>1994</YR>
<VL>88</VL>
<NO>4</NO>
<PG>293-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joubert-1985" NAME="Joubert 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;Joubert JR; Burger G; Shephard E. Inhalation therapy during acute asthma. The role of a combined steroid and beta-stimulant preparation. South African Medical Journal. 1985; 68(6):381-4.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joubert JR, Burger G, Shephard E</AU>
<TI>Inhalation therapy during acute asthma. The role of a combined steroid and beta-stimulant preparation</TI>
<SO>South African Medical Journal</SO>
<YR>1985</YR>
<VL>68</VL>
<NO>6</NO>
<PG>381-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerstjens-1994" NAME="Kerstjens 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Kerstjens HA; Postma DS; van Doormaal JJ; van Zanten AK; Brand PL;  Dekhuijzen PN; Koeter GH.Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group [see comments.Thorax. 1994;49(7):652-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerstjens HA, Postma DS, van Doormaal JJ, van Zanten AK, Brand PL, Dekhuijzen PN, et al</AU>
<TI>Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group [see comments]</TI>
<SO>Thorax</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>7</NO>
<PG>652-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kerstjens-1995" NAME="Kerstjens 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Kerstjens HA; Schouten JP; Brand PL; Schoonbrood DF; Sterk PJ; Postma DS. Importance of total serum IgE for improvement in airways  hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group.  American Journal of Respiratory and Critical Care Medicine. 1995;151(2Pt 1):360-8.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kerstjens HA, Schouten JP, Brand PL, Schoonbrood DF, Sterk PJ, Postma DS</AU>
<TI>Importance of total serum IgE for improvement in airways hyperresponsiveness with inhaled corticosteroids in asthma and chronic obstructive pulmonary disease. The Dutch CNSLD Study Group</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1995</YR>
<VL>151</VL>
<NO>2Pt 1</NO>
<PG>360-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kolaczkowska-1996" NAME="Kolaczkowska 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Kolaczkowska M; Mlynarczyk W; Rzymkowska M. Long-term corticosteroid therapy as a risk factor of osteoporosis in patients with asthma and chronic bronchitis.  Pneumonologia i Alergologia Polska.1996; 64(3-4):196-203.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kolaczkowska M, Mlynarczyk W, Rzymkowska M</AU>
<TI>Long-term corticosteroid therapy as a risk factor of osteoporosis in patients with asthma and chronic bronchitis</TI>
<SO>Pneumonologia i Alergologia Polska</SO>
<YR>1996</YR>
<VL>64</VL>
<NO>3-4</NO>
<PG>196-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kudo-1995" NAME="Kudo 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Kudo K; Hojo M; Kabe J. Inhaled beclomethasone in long-term management of asthma: optimal dose and optimal duration of treatment. Nippon Kyobu Shikkan Gakkai Zasshi. Japanese Journal of Thoracic Diseases. 1995;33(9):956-65.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kudo K, Hojo M, Kabe J</AU>
<TI>Inhaled beclomethasone in long-term management of asthma: optimal dose and optimal duration of treatment</TI>
<SO>Nippon Kyobu Shikkan Gakkai Zasshi (Japanese Journal of Thoracic Diseases)</SO>
<YR>1995</YR>
<VL>33</VL>
<NO>9</NO>
<PG>956-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laviolette-1994" NAME="Laviolette 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Laviolette M; Ferland C; Trepanier L; Rocheleau H; Dakhama A; Boulet LP. Effects of inhaled steroids on blood eosinophils in moderate asthma. Annals of the New York Academy of Sciences. 1994; 725:288-97.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laviolette M, Ferland C, Trepanier L, Rocheleau H, Dakhama A, Boulet LP</AU>
<TI>Effects of inhaled steroids on blood eosinophils in moderate asthma</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1994</YR>
<VL>725</VL>
<PG>288-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MacKenzie-1998" NAME="MacKenzie 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;MacKenzie, C., Journal. Effects of inhaled corticosteroids on growth. Journal of Allergy &amp;amp; Clinical Immunology. 1998;101(4 II)S451-S455.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MacKenzie C</AU>
<TI>Effects of inhaled corticosteroids on growth</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1998</YR>
<VL>101</VL>
<NO>4 II</NO>
<PG>S451-S455</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maestrelli-1993" NAME="Maestrelli 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Maestrelli P; De Marzo N; Saetta M; Boscaro M; Fabbri LM; Mapp CE.&lt;br&gt;Effects of inhaled beclomethasone on airway responsiveness in&lt;br&gt;occupational asthma. Placebo-controlled study of subjects sensitized to toluene diisocyanate.  American Review of Respiratory Disease. 1993;148(2):407-12.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maestrelli P, De Marzo N, Saetta M, Boscaro M, Fabbri LM, Mapp CE</AU>
<TI>Effects of inhaled beclomethasone on airway responsiveness in occupational asthma. Placebo-controlled study of subjects sensitized to toluene diisocyanate</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>148</VL>
<NO>2</NO>
<PG>407-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mahajan-1997" NAME="Mahajan 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Mahajan P; Okamoto LJ; Schaberg A; Kellerman D; Schoenwetter WF.  Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma.  Journal of Asthma. 1997,;34(3):227-34.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mahajan P, Okamoto LJ, Schaberg A, Kellerman D, Schoenwetter WF</AU>
<TI>Impact of fluticasone propionate powder on health-related quality of life in patients with moderate asthma</TI>
<SO>Journal of Asthma</SO>
<YR>1997,</YR>
<VL>34</VL>
<NO>3</NO>
<PG>227-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malka-1994" NAME="Malka 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Malka M. Treatment of asthma: research on the minimum effective dose of inhaled corticoids. Results with budesonide. Revue de Medecine Interne. 1994; 15 Suppl 2:252s-3s.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malka M</AU>
<TI>Treatment of asthma: research on the minimum effective dose of inhaled corticoids. Results with budesonide</TI>
<SO>Revue de Medecine Interne</SO>
<YR>1994</YR>
<VL>15 Suppl 2</VL>
<PG>252s-3s</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Malo-1996" NAME="Malo 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Malo, J. L., Cartier, A., Cote, J., Milot, J., Leblanc, C., Paquette, L., Ghezzo, H., and Boulet, L. P.  Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study.    American Journal of Respiratory &amp;amp; Critical Care Medicine 1996 Mar; 153:(3):953-60&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Malo JL, Cartier A, Cote J, Milot J, Leblanc C, Paquette L, et al</AU>
<TI>Influence of inhaled steroids on recovery from occupational asthma after cessation of exposure: an 18-month double-blind crossover study</TI>
<SO>American Journal of Respiratory &amp; Critical Care Medicine</SO>
<YR>1996 Mar</YR>
<VL>153</VL>
<NO>3</NO>
<PG>953-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Merkus-1993" NAME="Merkus 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Merkus PJ; van Essen-Zandvliet EE; Duiverman EJ; van Houwelingen HC; Kerrebijn KF; Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics, 1993; 91(6):1121-6.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, van Houwelingen HC, Kerrebijn KF, Quanjer PH</AU>
<TI>Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>91</VL>
<NO>6</NO>
<PG>1121-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moller-1996" NAME="Moller 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Moller GM; Overbeek SE; Van Helden-Meeuwsen CG; Van Haarst JM; Prens EP; Mulder PG; Postma DS; Hoogsteden HC. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids. Clinical and Experimental Allergy. 1996;26(5):517-24.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moller GM, Overbeek SE, Van Helden-Meeuwsen CG, Van Haarst JM, Prens EP, Mulder PG, et al</AU>
<TI>Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: downregulation by inhaled corticosteroids</TI>
<SO>Clinical and Experimental Allergy</SO>
<YR>1996</YR>
<VL>26</VL>
<NO>5</NO>
<PG>517-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nathan-1997" NAME="Nathan 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Nathan, R. A., Nolop, K. B., Cuss, F. M., and Lorber, R. R.  A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma [see comments].    Chest 1997 Jul; 112:(1):34-9&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nathan RA, Nolop KB, Cuss FM, Lorber RR</AU>
<TI>A comparison of double-strength beclomethasone dipropionate (84 microg) MDI with beclomethasone dipropionate (42 microg) MDI in the treatment of asthma [see comments]</TI>
<SO>Chest</SO>
<YR>1997 Jul</YR>
<VL>112</VL>
<NO>1</NO>
<PG>34-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nyholm-1984" NAME="Nyholm 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;Nyholm, E., Frame, M. H., and Cayton, R. M.  Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma.    European Journal of Respiratory Diseases 1984 Jul; 65:(5):339-45&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nyholm E, Frame MH, Cayton RM</AU>
<TI>Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma</TI>
<SO>European Journal of Respiratory Diseases</SO>
<YR>1984 Jul</YR>
<VL>65</VL>
<NO>5</NO>
<PG>339-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overbeek-1996" NAME="Overbeek 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Overbeek SE; Kerstjens HA; Bogaard JM; Mulder PG; Postma DS.&lt;br&gt;Is delayed introduction of inhaled corticosteroids harmful in patients&lt;br&gt;with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups. Chest. 1996; 110(1):35-41.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overbeek SE, Kerstjens HA, Bogaard JM, Mulder PG, Postma DS</AU>
<TI>Is delayed introduction of inhaled corticosteroids harmful in patients with obstructive airways disease (asthma and COPD)? The Dutch CNSLD Study Group. The Dutch Chronic Nonspecific Lung Disease Study Groups</TI>
<SO>Chest</SO>
<YR>1996</YR>
<VL>110</VL>
<NO>1</NO>
<PG>35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearlman-1997" NAME="Pearlman 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Pearlman DS; Noonan MJ; Tashkin DP; Goldstein MF; Hamedani AG; Kellerman  DJ; Schaberg A. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma. Annals of Allergy, Asthma, and Immunology, 1997; 78(4):356-62.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearlman DS, Noonan MJ, Tashkin DP, Goldstein MF, Hamedani AG, Kellerman DJ, et al</AU>
<TI>Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma</TI>
<SO>Annals of Allergy, Asthma, and Immunology</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>4</NO>
<PG>356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedersen-1996" NAME="Pedersen 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Pedersen B; Dahl R; Karlstrom R; Peterson CG; Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with&lt;br&gt;inhaled budesonide. The impact of smoking. American Journal of Respiratory and Critical Care Medicine. 1996;153(5):1519-29.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pedersen B, Dahl R, Karlstrom R, Peterson CG, Venge P</AU>
<TI>Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1996</YR>
<VL>153</VL>
<NO>5</NO>
<PG>1519-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pepys-1975" NAME="Pepys 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Pepys J.Effects of inhaled beclomethasone dipropionate on bronchial provocation test reactions.Postgraduate Medical Journal. 1975; 51 Suppl 4:42-8.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pepys J</AU>
<TI>Effects of inhaled beclomethasone dipropionate on bronchial provocation test reactions</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1975</YR>
<VL>51 Suppl 4</VL>
<PG>42-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponticiello-1997" NAME="Ponticiello 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;Ponticiello A; Vatrella A; Parrella R; Romano L; Zofra S; Berlingieri GM; Bariffi F. Inhaled beclomethasone dipropionate (BDP) prevents seasonal changes in atopic asthmatics. Monaldi Archives for Chest Disease. 1997; 52(2):112-7.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponticiello A, Vatrella A, Parrella R, Romano L, Zofra S, Berlingieri GM, et al</AU>
<TI>Inhaled beclomethasone dipropionate (BDP) prevents seasonal changes in atopic asthmatics</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1997</YR>
<VL>52</VL>
<NO>2</NO>
<PG>112-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Price-1997" NAME="Price 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Price JF, Russell G, Hindmarsh PC, Weller P, Heaf DP</AU>
<TI>Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma</TI>
<SO>Pediatric Pulmonology</SO>
<YR>1997</YR>
<VL>24</VL>
<NO>3</NO>
<PG>178-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prieto-1994" NAME="Prieto 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Prieto L; Berto JM; Gutierrez V; Tornero C. Effect of inhaled budesonide on seasonal changes in sensitivity and maximal response to methacholine in pollen-sensitive asthmatic subjects.European Respiratory Journal. 1994; 7(10):1845-51.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prieto L, Berto JM, Gutierrez V, Tornero C</AU>
<TI>Effect of inhaled budesonide on seasonal changes in sensitivity and maximal response to methacholine in pollen-sensitive asthmatic subjects</TI>
<SO>European Respiratory Journal</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>10</NO>
<PG>1845-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-1996" NAME="Reid 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Reid A; Murphy C; Steen HJ; McGovern V; Shields MD.&lt;br&gt;Linear growth of very young asthmatic children treated with high-dose nebulized budesonide. Acta Paediatrica. 1996;85(4):421-4.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid A, Murphy C, Steen HJ, McGovern V, Shields MD</AU>
<TI>Linear growth of very young asthmatic children treated with high-dose nebulized budesonide</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>4</NO>
<PG>421-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riordan-1974" NAME="Riordan 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Riordan JF; Dash CH; Sillett RW; McNicol MW. A comparison of betamethasone valerate, beclomethasone dipropionate and placebo by inhalation for the treatment of chronic asthma. Postgraduate Medical Journal. 1974;50 suppl 4:61-4.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riordan JF, Dash CH, Sillett RW, McNicol MW</AU>
<TI>A comparison of betamethasone valerate, beclomethasone dipropionate and placebo by inhalation for the treatment of chronic asthma</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1974</YR>
<VL>50</VL>
<NO>suppl 4</NO>
<PG>61-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roisman-1995" NAME="Roisman 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Roisman GL; Peiffer C; Lacronique JG; Le Cae A; Dusser DJ.&lt;br&gt;Perception of bronchial obstruction in asthmatic patients. Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment.  Journal of Clinical Investigation. 1995;96(1):12-21.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roisman GL, Peiffer C, Lacronique JG, Le Cae A, Dusser DJ</AU>
<TI>Perception of bronchial obstruction in asthmatic patients. Relationship with bronchial eosinophilic inflammation and epithelial damage and effect of corticosteroid treatment</TI>
<SO>Journal of Clinical Investigation</SO>
<YR>1995</YR>
<VL>96</VL>
<NO>1</NO>
<PG>12-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheffer-1996" NAME="Sheffer 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Sheffer AL; LaForce C; Chervinsky P; Pearlman D; Schaberg A. Fluticasone propionate aerosol: efficacy in patients with mild to&lt;br&gt;moderate asthma. Fluticasone Propionate Asthma Study Group.&lt;br&gt;Journal of Family Practice. 1996;42(4):369-75.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheffer AL, LaForce C, Chervinsky P, Pearlman D, Schaberg A</AU>
<TI>Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group</TI>
<SO>Journal of Family Practice</SO>
<YR>1996</YR>
<VL>42</VL>
<NO>4</NO>
<PG>369-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1987" NAME="Smith 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Smith MJ. The place of high-dose inhaled corticosteroids in asthma therapy. Drugs. 1987;33(5):423-9.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith MJ</AU>
<TI>The place of high-dose inhaled corticosteroids in asthma therapy</TI>
<SO>Drugs</SO>
<YR>1987</YR>
<VL>33</VL>
<NO>5</NO>
<PG>423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparkes-1974" NAME="Sparkes 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Sparkes CG. Plasma cortisol levels in normal subjects after inhaled corticosteroids. Postgraduate Medical Journal.1974; 50:9-11.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparkes CG</AU>
<TI>Plasma cortisol levels in normal subjects after inhaled corticosteroids</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1974</YR>
<VL>50</VL>
<PG>9-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Storr-1986" NAME="Storr 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Storr J, Lenney CA, Lenney W</AU>
<TI>Nebulised beclomethasone dipropionate in preschool asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>3</NO>
<PG>270-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sutochnikova-1996" NAME="Sutochnikova 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sutochnikova OA, Samsonova MV, Cherniak AV, Cherniaev AL, Sokolov AS, Chuchalin AG</AU>
<TI>The effect of the Russian inhalant glucocorticosteroid budesonide on bronchial inflammation and hyperreactivity during the long-term treatment of bronchial asthma patients</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>1996</YR>
<VL>68</VL>
<NO>3</NO>
<PG>48-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taskar-1993" NAME="Taskar 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Taskar VS; Mahashur AA; John PJ; Kolhatkar VP; Menon L; Bijur S.&lt;br&gt;Anti-inflammatory action of steroid inhalers. Journal of the Association of Physicians of India. 1993;41(5):281-3.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taskar VS, Mahashur AA, John PJ, Kolhatkar VP, Menon L, Bijur S</AU>
<TI>Anti-inflammatory action of steroid inhalers</TI>
<SO>Journal of the Association of Physicians of India</SO>
<YR>1993</YR>
<VL>41</VL>
<NO>5</NO>
<PG>281-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taylor-1975" NAME="Taylor 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;Taylor B; Norman AP.Betamethasone 17-valerate in childhood asthma. A double-blind crossover trial in children not taking other corticosteroid therapy. Acta Paediatrica Scandinavica, 1975;64(2):234-40.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taylor B, Norman AP</AU>
<TI>Betamethasone 17-valerate in childhood asthma. A double-blind crossover trial in children not taking other corticosteroid therapy</TI>
<SO>Acta Paediatrica Scandinavica</SO>
<YR>1975</YR>
<VL>64</VL>
<NO>2</NO>
<PG>234-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tinkelman-1993" NAME="Tinkelman 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Adelroth E; Thompson S.High-dosage inhalation steroids in asthma--analysis of costs and use in health care.  Lakartidningen, 1984; 81(46):4285-8.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Adelroth E, Thompson S</AU>
<TI>High-dosage inhalation steroids in asthma--analysis of costs and use in health care</TI>
<SO>Lakartidningen</SO>
<YR>1984</YR>
<VL>81</VL>
<NO>46</NO>
<PG>4285-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Todd-1997" NAME="Todd 1997" YEAR="1997">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Todd G, White CM, Milch LR</AU>
<TI>Fluticasone's effect on growth, pharmacokinetic profile questioned</TI>
<SO>Hospital Formulary</SO>
<YR>1997</YR>
<VL>32</VL>
<NO>4</NO>
<PG>319-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toogood-1987" NAME="Toogood 1987" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;Toogood, J. H.  Efficiency of inhaled versus oral steroid treatment of chronic asthma.    New England &amp;amp; Regional Allergy Proceedings 1987 Mar-Apr; 8:(2):98-103&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH</AU>
<TI>Efficiency of inhaled versus oral steroid treatment of chronic asthma</TI>
<SO>New England &amp; Regional Allergy Proceedings</SO>
<YR>1987 Mar-Apr</YR>
<VL>8</VL>
<NO>2</NO>
<PG>98-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toogood-1991" NAME="Toogood 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Toogood, J. H., Jennings, B., Hodsman, A. B., Baskerville, J., and Fraher, L. J.  Effects of dose and dosing schedule of inhaled budesonide on bone turnover.   J-Allergy-Clin-Immunol 1991; 88:572-80&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Jennings B, Hodsman AB, Baskerville J, Fraher LJ</AU>
<TI>Effects of dose and dosing schedule of inhaled budesonide on bone turnover</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>572-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trigg-1994" NAME="Trigg 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Trigg CJ; Manolitsas ND; Wang J; Calderon MA; McAulay A; Jordan SE; Herdman MJ; Jhalli N; Duddle JM; Hamilton SA; et al.&lt;br&gt;Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. American Journal of Respiratory and Critical Care Medicine. 1994;150(1):17-22.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trigg CJ, Manolitsas ND, Wang J, Calderon MA, McAulay A, Jordan SE, et al</AU>
<TI>Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma</TI>
<SO>American Journal of Respiratory and Critical Care Medicine</SO>
<YR>1994</YR>
<VL>150</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Essen_x002d_Zand-1986" NAME="Van Essen-Zand 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;van Essen-Zandvliet EE. Hughes MD. Waalkens HJ. Duiverman EJ. Pocock SJ. Kerrebijn KF. Effects of 22 months of treatment with inhaled&lt;br&gt;corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung&lt;br&gt;Disease Study Group. [see comments.]. [Clinical Trial. Journal Article. Randomized Controlled Trial] American Review of Respiratory Disease. 146(3):547-54,&lt;br&gt;1992 Sep. &lt;br&gt;UI: 1355640 &lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ</AU>
<TI>Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<NO>3</NO>
<PG>547-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Essen_x002d_Zand-1992" NAME="Van Essen-Zand 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Pocock SJ</AU>
<TI>Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<NO>3</NO>
<PG>547-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Essen_x002d_Zand-1994" NAME="Van Essen-Zand 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, Duiverman EJ, Kerrebijn KF</AU>
<TI>Remission of childhood asthma after long-term treatment with an inhaled corticosteroid (budesonide): can it be achieved? Dutch CNSLD Study Group</TI>
<SO>European Respiratory Journal</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>1</NO>
<PG>63-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Essen_x002d_Zandv-1995" NAME="Van Essen-Zandv 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Essen-Zandvliet EE</AU>
<TI>Long-term intervention in childhood asthma: the Dutch study results. Dutch Chronic Nonspecific Lung Disease Study Group</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>3</NO>
<PG>201-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waalkens-1993" NAME="Waalkens 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waalkens HJ, van Essen-Zandvliet EE, Gerritsen J, Duiverman EJ, Kerrebijn KF, Knol K</AU>
<TI>The effect of an inhaled corticosteroid (budesonide) on exercise-induced asthma in children. Dutch CNSLD Study Group [see comments]</TI>
<SO>European Respiratory Journal</SO>
<YR>1993</YR>
<VL>6</VL>
<NO>5</NO>
<PG>652-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1994" NAME="Wang 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang JH, Trigg CJ, Devalia JL, Jordan S, Davies RJ</AU>
<TI>Effect of inhaled beclomethasone dipropionate on expression of proinflammatory cytokines and activated eosinophils in the bronchial epithelium of patients with mild asthma. Journal of Allergy and Clinical Immunology</TI>
<SO>Journal of Allergy and Clinical Immunology</SO>
<YR>1994</YR>
<VL>94</VL>
<NO>6 Pt 1</NO>
<PG>1025-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wasserman-1996" NAME="Wasserman 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wasserman SI, Gross GN, Schoenwetter WF, Munk ZM, Kral KM, Schaberg A, et al</AU>
<TI>A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma</TI>
<SO>Journal of Asthma</SO>
<YR>1996</YR>
<VL>33</VL>
<NO>4</NO>
<PG>265-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1986" NAME="Webb 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb MS, Milner AD, Hiller EJ, Henry RL</AU>
<TI>Nebulised beclomethasone dipropionate suspension</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1108-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wennergren-1996" NAME="Wennergren 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wennergren G, Nordvall SL, Hedlin G, Moller C, Wille S, Asbrink Nilsson E</AU>
<TI>Nebulized budesonide for the treatment of moderate to severe asthma in infants and toddlers</TI>
<SO>Acta Paediatrica</SO>
<YR>1996</YR>
<VL>85</VL>
<NO>2</NO>
<PG>183-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilken_x002d_Jensen-1975" NAME="Wilken-Jensen 1975" YEAR="1975">
<REFERENCE NOTES="&lt;p&gt;26. Wilken-Jensen K.The effect of inhalations of beclomethasone dipropionate on plasma cortisol levels and growth hormone production. Postgraduate Medical Journal. 1975; 51 Suppl 4:31-2.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilken-Jensen K</AU>
<TI>The effect of inhalations of beclomethasone dipropionate on plasma cortisol levels and growth hormone production</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1975</YR>
<VL>51</VL>
<NO>Suppl 4</NO>
<PG>31-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wilson-1995" NAME="Wilson 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Wilson, N., Sloper, K., and Silverman, M.  Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children.   Arch-Dis-Child 1995; 72:317-20&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wilson N, Sloper K, Silverman M</AU>
<TI>Effect of continuous treatment with topical corticosteroid on episodic viral wheeze in preschool children</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1995</YR>
<VL>72</VL>
<PG>317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolfe-1996" NAME="Wolfe 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Wolfe JD; Selner JC; Mendelson LM; Hampel F Jr; Schaberg A.&lt;br&gt;Effectiveness of fluticasone propionate in patients with moderate&lt;br&gt;asthma: a dose-ranging study. Clinical Therapeutics, 1996;18(4):635-46.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolfe JD, Selner JC, Mendelson LM, Hampel F Jr, Schaberg A</AU>
<TI>Effectiveness of fluticasone propionate in patients with moderate asthma: a dose-ranging study</TI>
<SO>Clinical Therapeutics</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>4</NO>
<PG>635-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolthers-1995" NAME="Wolthers 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolthers OD, Pedersen S</AU>
<TI>Measures of systemic activity of inhaled glucocorticosteroids in children: A comparison of urine cortisol excretion and knemometry</TI>
<SO>Respiratory Medicine</SO>
<YR>1995</YR>
<VL>89</VL>
<NO>5</NO>
<PG>347-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wong-1992" NAME="Wong 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wyatt-1978" NAME="Wyatt 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;Wyatt R; Waschek J; Weinberger M; Sherman B.Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma. New England Journal of Medicine. 1978; 299(25):1387-92.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wyatt R, Waschek J, Weinberger M, Sherman B</AU>
<TI>Effects of inhaled beclomethasone dipropionate and alternate-day prednisone on pituitary-adrenal function in children with chronic asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1978</YR>
<VL>299</VL>
<NO>25</NO>
<PG>1387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yazigi-1978" NAME="Yazigi 1978" YEAR="1978">
<REFERENCE NOTES="&lt;p&gt;9. Yazigi R; Sly RM; Frazer M. Effect of triamcinolone acetonide aerosol upon exercise-induced asthma. Annals of Allergy. 1978;40(5):322-5.&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yazigi R, Sly RM, Frazer M</AU>
<TI>Effect of triamcinolone acetonide aerosol upon exercise-induced asthma</TI>
<SO>Annals of Allergy</SO>
<YR>1978</YR>
<VL>40</VL>
<NO>5</NO>
<PG>322-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson">
<ADDITIONAL_REFERENCES MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson">
<REFERENCE ID="REF-Ali-1991" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Ali 1991" NOTES="&lt;p&gt;Ali NJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax. 1991;46:160-4&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Ali NJ</AU>
<TI>Bone turnover during high dose inhaled corticosteroid treatment.</TI>
<SO>Thorax</SO>
<YR>1991</YR>
<VL>46</VL>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-1994" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Allen 1994" NOTES="&lt;p&gt;Allen E, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-76Allen DB. Mullen M. Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. [Journal Article. Meta-Analysis] Journal&lt;br&gt;of Allergy &amp;amp; Clinical Immunology. 93(6):967-76, 1994 Jun. &lt;br&gt;UI: 8006318&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Allen E, Mullen M, Mullen B</AU>
<TI>A meta-analysis of the effect of oral and inhaled corticosteroids on growth</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>6</NO>
<PG>967-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-1996" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Allen 1996" NOTES="&lt;p&gt;Allen DB,. Growth suppression by glucocorticoid therapy. In: Vassallo J, eds. Endocrinology and metabolism clinics in North America. Philadelphia: W.B. Saunders Co 1996;699-717&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK_SECTION">
<AU>Allen DB</AU>
<TI>Growth suppression by glucocorticoid therapy</TI>
<SO>Endocrinology and metabolism clinics in North America</SO>
<YR>1996</YR>
<PG>699-717</PG>
<ED>Vassallo J, eds</ED>
<PB>W.B. Saunders Co</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Balfour_x002d_Lynn-1986" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Balfour-Lynn 1986" NOTES="&lt;p&gt;Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986;61(11):1049-55&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Balfour-Lynn L</AU>
<TI>Growth and childhood asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1049-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Barnes-1993" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Barnes 1993" NOTES="&lt;p&gt;Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Am Rev Respir Dis 1993;148:S1-S26&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Barnes PJ, Pedersen S</AU>
<TI>Efficacy and safety of inhaled corticosteroids in asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1993</YR>
<VL>148</VL>
<PG>S1-S26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Begg-1989" NAME="Begg 1989" NOTES="&lt;p&gt;Begg, C. B., and J. A. Berlin. 1988. &amp;#8220;Publication Bias: A Problem in Interpreting Medical Data.&amp;#8221; Journal of the Royal Statistical Society, Series A 151:419&amp;#8211;445.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Begg CB, Berlin JA</AU>
<TI>Publication bias: a problem in interpreting medical data</TI>
<SO>Journal of the Royal Statistical Society, Series A</SO>
<YR>1988</YR>
<VL>151</VL>
<PG>419-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beveridge-1996" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Beveridge 1996" NOTES="&lt;p&gt;Beveridge RC, Grunfeld AF, Hodder RV, et al. Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society. Canadian Medical Association Journal 1996;155(1):25-37&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Beveridge RC, Grunfeld AF, Hodder RV, et al</AU>
<TI>Guidelines for the emergency management of asthma in adults. CAEP/CTS Asthma Advisory Committee. Canadian Association of Emergency Physicians and the Canadian Thoracic Society</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>1996</YR>
<VL>155</VL>
<NO>1</NO>
<PG>25-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boorsma-1996" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Boorsma 1996" NOTES="&lt;p&gt;Boorsma M, Andersson N, Larsson P, et al. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J 1996;9:1427-32&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Boorsma M, Andersson N, Larsson P, et al</AU>
<TI>Assessment of the relative systemic potency of inhaled fluticasone and budesonide</TI>
<SO>European Respiratory Journal</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>1427-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-British-Thor-Soc1993" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="British Thor Soc1993" NOTES="&lt;p&gt;Guidelines on the management of asthma. Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group. Thorax 1993; 48(2 Suppl):S1-S24.&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Guidelines on the management of asthma</AU>
<TI>Statement by the British Thoracic Society, the British Paediatric Association, the Research Unit of the Royal College of Physicians of London, the King's Fund Centre, the National Asthma Campaign, the Royal College of General Practitioners, the General Practitioners in Asthma Group, the British Association of Accident and Emergency Medicine, and the British Paediatric Respiratory Group</TI>
<SO>Thorax</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>2 Suppl</NO>
<PG>S1-S24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-1993" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Brown 1993" NOTES="&lt;p&gt;Brown PH, Matusiewicz SP, Shearing C, et al. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993;48:967-73&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Brown PH, Matusiewicz SP, Shearing C, et al</AU>
<TI>Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects</TI>
<SO>Thorax</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>967-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Capewell-1990" NAME="Capewell 1990" NOTES="&lt;p&gt;Capewell S, Reynolds S, Shuttleworth D, et al. Purpura and dermal thinning associated with high dose inhaled corticosteroids. BMJ 1990;300:1548-51&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Capewell S, Reynolds S, Shuttleworth D, et al</AU>
<TI>Purpura and dermal thinning associated with high dose inhaled corticosteroids</TI>
<SO>BMJ</SO>
<YR>1990</YR>
<VL>300</VL>
<PG>1548-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-1996" NAME="Clark 1996" NOTES="&lt;p&gt;Clark DJ, Grove A, Cargill RI et al. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 1996;51:262-6&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Clark DJ, Grove A, Cargill RI et al</AU>
<TI>Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients</TI>
<SO>Thorax</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>262-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dahl-1993" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Dahl 1993" NOTES="&lt;p&gt;Dahl R, Lundback E, Malo JL, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993;104:1352-8&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Dahl R, Lundback E, Malo JL, et al</AU>
<TI>A dose-ranging study of fluticasone propionate in adult patients with moderate asthma</TI>
<SO>Chest</SO>
<YR>1993</YR>
<VL>104</VL>
<PG>1352-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" NAME="DerSimonian 1986" NOTES="&lt;p&gt;DerSominan R, Laird N. Meta-Analysis in clinical trials. Controlled Clinical Trials 1986;7:177-188&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>DerSominan R, Laird N</AU>
<TI>Meta-Analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doull-1998" NAME="Doull 1998" TYPE="JOURNAL_ARTICLE">
<AU>Doull IJM, Campbell MJ, Holgate ST</AU>
<TI>Duration of growth suppresive effects of regular inhaled corticosteroids</TI>
<SO>Archives of Diseases of Childhood</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>2</NO>
<PG>172-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doull-IJM_x002c_-Camp2" NAME="Doull IJM, Camp2" TYPE="JOURNAL_ARTICLE">
<AU>Doull IJM, Campbell MJ, Holgate ST</AU>
<TI>Duration of growth suppresive effects of regular inhaled corticosteroids</TI>
<SO>Archives of Diseases of Childhood</SO>
<YR>1998</YR>
<VL>78</VL>
<NO>2</NO>
<PG>172-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fabbri-1993" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Fabbri 1993" NOTES="&lt;p&gt;Fabbri L, Burge PS, Croonenborgh L, et al.  Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Thorax 1993;48:817-23&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Fabbri L, Burge PS, Croonenborgh L, et al</AU>
<TI>Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year</TI>
<SO>Thorax</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>817-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-1998" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="FDA 1998" NOTES="&lt;p&gt;Federal Drug Administration, United States Department of Health and Human Services November 9, 1998.FDA Talk Paper. FDA requires new pediatric labeling for inhaled, intranasal corticosteroids. FDA website, http//www.fda.gov&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="OTHER">
<AU>Federal Drug Administration, United States Department of Health and Human Services November 9, 1998</AU>
<TI>FDA requires new pediatric labeling for inhaled, intranasal corticosteroids.</TI>
<SO>FDA Talk Paper. FDA website, http//www.fda</SO>
<YR>1988</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gustafsson-1993" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Gustafsson 1993" NOTES="&lt;p&gt;Gustafsson P, Tsanakas J, Gold M, et al. Comparison of the efficacy and safety of inhaled fluticasone 200 mcg/day with inhaled beclomethasone dipropionate 400 mcg/day in mild and moderate asthma. Arch Dis Child 1993;69:206-11&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Gustafsson P, Tsanakas J, Gold M, et al</AU>
<TI>Comparison of the efficacy and safety of inhaled fluticasone 200 mcg/day with inhaled beclomethasone dipropionate 400 mcg/day in mild and moderate asthma</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1993</YR>
<VL>69</VL>
<PG>206-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haahtela-1991" NAME="Haahtela 1991" NOTES="&lt;p&gt;Haahtela T, Jarvinen M, Kava T, et al. Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991;325:388-92&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Haahtela T, Jarvinen M, Kava T, et al</AU>
<TI>Comparison of a beta2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<PG>388-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hill-1965" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Hill 1965" NOTES="&lt;p&gt;Hill, AB. The environment and disease: Association of causation. Proc R Soc Med 1965;58:295-300&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Hill, AB</AU>
<TI>The environment and disease: Association of causation</TI>
<SO>Proceedings of the Royal Society of Medicine</SO>
<YR>1965</YR>
<VL>58</VL>
<PG>295-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Japan-Soc-All-1995" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Japan Soc All 1995" NOTES="&lt;p&gt;Japanese Society of Allergology. Guidelines for the diagnosis and management of bronchial asthma. Committee on the definition, treatment, and management of bronchial asthma. Japanese Society of Allergology. Allergy. 1995;50(27):1-42&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Japanese Society of Allergology</AU>
<TI>Guidelines for the diagnosis and management of bronchial asthma. Committee on the definition, treatment, and management of bronchial asthma</TI>
<SO>Allergy</SO>
<YR>1995</YR>
<VL>50</VL>
<NO>27</NO>
<PG>1-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jeffery-1992" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Jeffery 1992" NOTES="&lt;p&gt;Jeffery PK, Godfrey RW, Adelroth E, et al. Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. Am Rev Respir Dis 1992;145:890-9&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Jeffery PK, Godfrey RW, Adelroth E, et al</AU>
<TI>Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>145</VL>
<PG>890-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamada-1994" NAME="Kamada 1994" NOTES="&lt;p&gt;Kamada, AK.  Therapeutic controversies in the treatment of asthma. Annals of Pharmacotherapy. 1994;28(7-8):904-14.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kamada, AK</AU>
<TI>Therapeutic controversies in the treatment of asthma</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1994</YR>
<VL>28</VL>
<NO>7-8</NO>
<PG>904-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kamada-1995" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Kamada 1995" NOTES="&lt;p&gt;Kamada AK, Szefler SJ. Glucocorticoids and growth in asthmatic children. Pediatr Allergy Immunol 1995;6:145-54&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Kamada AK, Szefler SJ</AU>
<TI>Glucocorticoids and growth in asthmatic children</TI>
<SO>Pediatric Allergy &amp; Immunology</SO>
<YR>1995</YR>
<VL>6</VL>
<PG>145-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laird-1990" NAME="Laird 1990" NOTES="&lt;p&gt;Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Tech Assess in Health Care 1990;6(1):5-30&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Laird NM, Mosteller F</AU>
<TI>Some statistical methods for combining experimental results</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>1990</YR>
<VL>6</VL>
<NO>1</NO>
<PG>5-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Last-1995" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Last 1995" NOTES="&lt;p&gt;Last JM editor. A dictionary of epidemiology, third edition. Oxford University Press, New York, NY. 1995&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK">
<AU>Last JM (editor)</AU>
<SO>A dictionary of epidemiology</SO>
<YR>1995</YR>
<EN>Third edition.</EN>
<PB>Oxford University Press,</PB>
<CY>New York, NY</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Mulrow 1997" NOTES="&lt;p&gt;Mulrow CD, Oxman AD (eds). Cochrane Collaboration Handbook [updated 1 march 1997]. In: The Cochrane Library [database on disk and CDROM]. The Cochrane Collaboration. Oxford: Update Software; 1996-. Updated quarterly.&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK_SECTION">
<AU>Mulrow CD, Oxman AD (eds)</AU>
<TI>Cochrane Collaboration Handbook [updated 1 march 1997]. In: The Cochrane Library [database on disk and CDROM].</TI>
<SO>The Cochrane Collaboration.</SO>
<YR>1997</YR>
<PG>Update Software; 1996-. Updated quarterly</PG>
<ED>Mulrow CD, Oxman AD (eds)</ED>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nat-Inst-Health-1991" NAME="Nat Inst Health 1991" NOTES="&lt;p&gt;National Institutes of Health 1991. National Asthma Education and Prevention Program. Expert Panel Report I: Guidelines for the diagnosis and management of asthma. National Institutes of Health. Bethesda, MD, 1991&lt;/p&gt;" TYPE="BOOK">
<AU>National Asthma Education and Prevention Program. National Institutes of Health</AU>
<SO>Expert Panel Report I: Guidelines for the diagnosis and management of asthma</SO>
<YR>1991</YR>
<PB>National Institutes of Health</PB>
<CY>Bethesda, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nat-Inst-Health-1997" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Nat Inst Health 1997" NOTES="&lt;p&gt;National Institutes of Health 1997. National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the diagnosis and management of asthma. National Institutes of Health. Bethesda, MD, 1997&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="BOOK">
<AU>National Institutes of Health</AU>
<SO>National Asthma Education and Prevention Program. Expert Panel Report II: Guidelines for the diagnosis and management of asthma</SO>
<YR>1997</YR>
<PG>Guidelines for the diagnosis and management of asthma</PG>
<PB>National Institutes of Health</PB>
<CY>Bethesda, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Packe-1992" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Packe 1992" NOTES="&lt;p&gt;Packe GE, Douglas JG, McDonald AF, et al. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax. 1992;47:414-417&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Packe GE, Douglas JG, McDonald AF, et al</AU>
<TI>Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids</TI>
<SO>Thorax</SO>
<YR>1992</YR>
<VL>47</VL>
<PG>414-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pouw-1991" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Pouw 1991" NOTES="&lt;p&gt;Pouw EM, Prummel MF, Oosting H, Roos CM, Endert E. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ. 1991;302:627-8&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Pouw EM, Prummel MF, Oosting H, Roos CM, Endert E</AU>
<TI>Beclomethasone inhalation decreases serum osteocalcin concentrations</TI>
<SO>BMJ</SO>
<YR>1991</YR>
<VL>302</VL>
<PG>627-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prahl-1991" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Prahl 1991" NOTES="&lt;p&gt;Prahl P. Adrenocortical suppression following treatment with beclomethasone dipropionate and budesonide. Clin Exp Allergy 1991;21:145-6&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Prahl P</AU>
<TI>Adrenocortical suppression following treatment with beclomethasone dipropionate and budesonide</TI>
<SO>Clinical &amp; Experimental Allergy</SO>
<YR>1991</YR>
<VL>21</VL>
<PG>145-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Puolijoki-1992" NAME="Puolijoki 1992" NOTES="&lt;p&gt;Puolijoki H, Liippo K, Herrala J, et al. inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women. Bone 1992;13(4)285-8&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Puolijoki H, Liippo K, Herrala J, et al</AU>
<TI>Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women</TI>
<SO>Bone</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>4</NO>
<PG>285-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raffery-1985" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Raffery 1985" NOTES="&lt;p&gt;Raffery P, Tucker LG, Frame MH, et al. Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisone-sparing effects. Br J Dis Chest 1985;79:244-50&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Raffery P, Tucker LG, Frame MH, et al</AU>
<TI>Comparison of budesonide and beclomethasone dipropionate in patients with severe chronic asthma: assessment of relative prednisone-sparing effects</TI>
<SO>British Journal of Diseases of the Chest</SO>
<YR>1985</YR>
<VL>79</VL>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodrigo_x002c_-1998" NAME="Rodrigo, 1998" NOTES="&lt;p&gt;Rodrigo, C; Rodrigo, G.  Salbutamol treatment of acute severe asthma in the ED:&lt;br&gt;MDI versus hand-held nebulizer. American Journal of Emergency Medicine. 1998;16(7):637-42.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rodrigo, C; Rodrigo, G</AU>
<TI>Salbutamol treatment of acute severe asthma in the ED: MDI versus hand-held nebulizer</TI>
<SO>American Journal of Emergency Medicine</SO>
<YR>1998</YR>
<VL>16</VL>
<NO>7</NO>
<PG>637-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rooklin-1979" NAME="Rooklin 1979" NOTES="&lt;p&gt;Rooklin AR, Lampert SI, Jeager EA, et al. Posterior subcapsular cataracts in steroid-requiring asthmatic children. J Allergy Clin Immunol 1979;63(6)383-6&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rooklin AR, Lampert SI, Jeager EA, et al</AU>
<TI>Posterior subcapsular cataracts in steroid-requiring asthmatic children</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1979</YR>
<VL>63</VL>
<NO>6</NO>
<PG>383-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-S-African-Pulm-1992" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="S African Pulm 1992" NOTES="&lt;p&gt;South African Pulmonology Society 1992. Guidelines for the management of asthma in adults in South Africa. Part I. Chronic Persistent Asthma. Working group of the South African Pulmonology Society. South African Medical Journal 1992;81:319-322&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>South African Pulmonology Society 1992</AU>
<TI>Guidelines for the management of asthma in adults in South Africa. Part I. Chronic Persistent Asthma. Working group of the South African Pulmonology Society</TI>
<SO>South African Medical Journal</SO>
<YR>1992</YR>
<VL>81</VL>
<PG>319-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1986" NAME="Shaw 1986" NOTES="&lt;p&gt;Shaw NJ, Edmunds AT Inhaled beclomethasone and oral candidiasis. Arch Dis Child 1986;61:788-90&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shaw NJ, Edmunds AT Inhaled beclomethasone and oral candidiasis</AU>
<TI>Inhaled beclomethasone and oral candidiasis</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1986</YR>
<VL>61</VL>
<PG>788-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-1993" NAME="Simons 1993" NOTES="&lt;p&gt;Simons FE, Persaud MP, Gillspie CA, et al. Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids. Lancet 1993;342:776-8&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Simons FE, Persaud MP, Gillspie CA, et al</AU>
<TI>Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids</TI>
<SO>Lancet</SO>
<YR>1993</YR>
<VL>342</VL>
<PG>776-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tabachnik-1991" MODIFIED="2008-07-21 13:49:30 +0100" MODIFIED_BY="Toby J Lasserson" NAME="Tabachnik 1991" NOTES="&lt;p&gt;Tabachnik E, Zadik Z,. Diurnal cortical secretion during therapy with inhaled beclomethasone dipropionate in children with asthma. J Pediatr 1991;118:294-7&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:30 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Tabachnik E, Zadik Z</AU>
<TI>Diurnal cortical secretion during therapy with inhaled beclomethasone dipropionate in children with asthma</TI>
<SO>Journal of Pediatrics</SO>
<YR>1991</YR>
<VL>118</VL>
<PG>294-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tinkelman-1993" NAME="Tinkelman 1993" NOTES="&lt;p&gt;Tinkelman DG, Red CE, Nelson HS, et al. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic mild to moderately severe asthma in children. Pediatrics 1993;92:64-77&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tinkelman DG, Red CE, Nelson HS, et al</AU>
<TI>Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic mild to moderately severe asthma in children</TI>
<SO>Pediatrics</SO>
<YR>1993</YR>
<VL>92</VL>
<PG>64-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toogood-1980" NAME="Toogood 1980" NOTES="&lt;p&gt;Toogood JH, Jennings B, Greenway RW, et al. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J Allergy Clin Immunol 1980;65:145-53&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Jennings B, Greenway RW, et al</AU>
<TI>Candidiasis and dysphonia complicating beclomethasone treatment of asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1980</YR>
<VL>65</VL>
<PG>145-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toogood-1988" NAME="Toogood 1988" NOTES="&lt;p&gt;Toogood JH, Crilly RG, Jones G, et al. Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am Rev Respir Dis 1988;139(1)57-61&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Crilly RG, Jones G, et al</AU>
<TI>Effect of high-dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1988</YR>
<VL>139</VL>
<NO>1</NO>
<PG>57-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toogood-1991" NAME="Toogood 1991" NOTES="&lt;p&gt;Toogood JH, Jennings B, Hodsman AB, et al. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 1991;88:572-80&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Jennings B, Hodsman AB, et al</AU>
<TI>Effects of dose and dosing schedule of inhaled budesonide on bone turnover</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>572-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toogood-1993" NAME="Toogood 1993" NOTES="&lt;p&gt;Toogood JH, Markov AE, Baskerville J, et al. Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma. J Allergy Clin Immunol 1993;91:571-9&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Markov AE, Baskerville J, et al</AU>
<TI>Association of ocular cataracts with inhaled and oral steroid therapy during long-term treatment of asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1993</YR>
<VL>91</VL>
<PG>571-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Toogood-1995" NAME="Toogood 1995" NOTES="&lt;p&gt;Toogood JH, Baskerville JC, Markov AE, et al. Bone mineral density and the risk of fracture in patients receiving long term inhaled steroid therapy for asthma. J allergy Clin Immunol 1995;96:157-66&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Toogood JH, Baskerville JC, Markov AE, et al</AU>
<TI>Bone mineral density and the risk of fracture in patients receiving long term inhaled steroid therapy for asthma</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1995</YR>
<VL>96</VL>
<PG>157-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turpeinen1991" NAME="Turpeinen1991" NOTES="&lt;p&gt;Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol 1991;88:384-9&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Turpeinen M, Sorva R, Juntunen-Backman K</AU>
<TI>Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide</TI>
<SO>Journal of Allergy &amp; Clinical Immunology</SO>
<YR>1991</YR>
<VL>88</VL>
<PG>384-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-V-Essen_x002d_Zand-1992" MODIFIED="2008-07-21 13:49:29 +0100" MODIFIED_BY="Toby J Lasserson" NAME="V Essen-Zand 1992" NOTES="&lt;p&gt;Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and /or beta2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-54&lt;/p&gt;" NOTES_MODIFIED="2008-07-21 13:49:29 +0100" NOTES_MODIFIED_BY="Toby J Lasserson" TYPE="JOURNAL_ARTICLE">
<AU>Van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al</AU>
<TI>Effects of 22 months of treatment with inhaled corticosteroids and /or beta2-agonists on lung function, airway responsiveness, and symptoms in children with asthma</TI>
<SO>American Review of Respiratory Disease</SO>
<YR>1992</YR>
<VL>146</VL>
<PG>547-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-1988" NAME="Walker 1988" NOTES="&lt;p&gt;Walker AM, Mertin-Morena JM, Artalejo FR. Odd man out: a graphical approach to meta-analysis. Am J Public Health 1988;78(8):961-6&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Walker AM, Mertin-Morena JM, Artalejo FR</AU>
<TI>Odd man out: a graphical approach to meta-analysis</TI>
<SO>American Journal of Public Health</SO>
<YR>1988</YR>
<VL>78</VL>
<NO>8</NO>
<PG>961-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woolcock-1989" NAME="Woolcock 1989" NOTES="&lt;p&gt;Woolcock A, Abraham R, Rubinfeld J, et al. Thoracic Society of Australia and New Zealand. Asthma management plan, 1989. Med J Aust;151:650-653&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Woolcock A, Abraham R, Rubinfeld J, et al</AU>
<TI>Thoracic Society of Australia and New Zealand. Asthma management plan</TI>
<SO>Medical Journal of Australia</SO>
<YR>1989</YR>
<VL>151</VL>
<PG>650-3</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-07-21 13:51:19 +0100" MODIFIED_BY="Toby J Lasserson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-07-21 13:51:19 +0100" MODIFIED_BY="Toby J Lasserson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Doull-1995">
<CHAR_METHODS>
<P>Randomized, double blind, clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Age 7-9 years, replied to questionnaire, &gt; or = 5 wheezing episodes in past year OR wheeze exacerbation lasting&gt; or = 3 days in past year. Exclusion criteria: use of inhaled steroids (ever), use of systemic steroids (ever), severe respiratory distress</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>7 months of placebo or MDI Beclomethasone at 200 micrograms BID</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Intervention group: Linear growth of 4.12 cm/yr<BR/>Placebo group: Linear growth of 5.94 cm/yr</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Asthma severity= mild (definition not stated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 13:51:04 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Simons-1997">
<CHAR_METHODS>
<P>Randomized, double blind, placebo controlled, clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Ages 6-14 years, clinically stable asthma, less than 1 month inhaled or systemic corticosteroids ever, no steroids &gt;3months prior to study, FEV1&gt;70 6 hours after B agonist held, 10% increase FEV1 30 minutes after B agonist, &lt;8mg methacholine to decrease FEV1 20%, ability to refrain from study meds for 36 hours, ability to stop albuterol 6 hours prior to visit<BR/>Exclusion criteria: ER/hosp in last 3 months, Hx life threatening asthma, hx life threatening reaction to study meds in the past</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Intervention: Beclomethasone 200 micrograms BID via diskhaler for 1 year<BR/>Group 2: Serevent 50 micrograms BID via diskhaler for 1 year<BR/>Placebo (lactose): 1 puff BID via diskhaler for 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Intervention: 3.96 cm/year growth<BR/>Group 2: 5.40 cm/year growth<BR/>Placebo: 5.04 cm/year growth</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-21 13:51:04 +0100" MODIFIED_BY="Toby J Lasserson">
<P>Standard deviations of treatment and control groups assumed to be equal, then calculated based on data reported in text of publication. Authors unable to be contacted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-07-21 13:51:19 +0100" MODIFIED_BY="Toby J Lasserson" STUDY_ID="STD-Verberne-1997">
<CHAR_METHODS>
<P>Randomized, double-blind, controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-07-21 13:51:19 +0100" MODIFIED_BY="Toby J Lasserson">
<P>6 years-16 years old, mild-moderate asthma, chosen from outpatient clinic of 6 university hospitals and 3 general hospitals, FEV1 55-90% or FEV1/FVC 50-75%, increase FEV1&gt;10% with .8mg salbutamol, decrease FEV1&gt;20% after 150 micrograms methacholine, ability to produce reproducible lung fxn tests as determined by &lt;5% variation on 3 consecutive FEV1, hx stable asthma&gt;1 mo without exacerbations or respiratory tract infxns, no inhaled steroids for &gt;6 months, no cromoglycate&gt;2 weeks</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Beclomethasone rotadisk/diskhaler 200micrograms BID<BR/>Salmeterol rotadisk/diskhaler 50 micrograms BID<BR/>for 1 year</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Intervention: 4.70 cm/year growth<BR/>Control: 6.10 cm/year growth</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Agertoft-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ahrens-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Allen-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 2 weeks ramp up time</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Apold-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arkins-1968">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bennati-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benoist-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>editorial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bisgaard-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not an asthma trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bisgaard-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Boner-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not measured</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Booms-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Clark-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inh steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crowley-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Crowley-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Damsbo-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Blic-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>no ramp up off inh steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doull-1995_x0028_2_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 1 day inh steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doull-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subpopulation of included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Doull-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subpopulation of other trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Droszcz-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Du-toit-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eefthimiou-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Falliers-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inh steroid, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Field-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>no ramp up time, inhaled steroid controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Francis-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 8 weeks inhaled steroid, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frank_x002d_Piskorska-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Freezer-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Galant-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>ramp up time less than 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ggajanan-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 2 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haahtela-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Henriksen-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>inh steroid only 3 weeks, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hoekstra-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Horn-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ishihara-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joubert-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 1 dose inh steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kerstjens-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inh steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kerstjens-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kolaczkowska-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kudo-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Laviolette-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-MacKenzie-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Maestrelli-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mahajan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>subgroup of included study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malka-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Malo-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Merkus-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 2 weeks ramp up with steroid free</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moller-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nathan-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nyholm-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Overbeek-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pearlman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>no ramp up time off steroids, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pedersen-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pepys-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ponticiello-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Price-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>inhaled steroid controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prieto-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reid-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riordan-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 2 weeks inh steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roisman-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sheffer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Smith-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sparkes-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an asthma trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Storr-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>inhaled steroid controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sutochnikova-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taskar-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inh steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Taylor-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 8 weeks inh steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tinkelman-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Ramp up time only 1 month</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Todd-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toogood-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>steroid controls</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Toogood-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 4 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trigg-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Essen_x002d_Zand-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 8 weeks inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Essen_x002d_Zand-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 2 weeks ramp up time</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Essen_x002d_Zand-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Van-Essen_x002d_Zandv-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>subpopulation of included article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waalkens-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wang-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>adults</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wasserman-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>ramp up time less than 1 month off inh steroids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Webb-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an asthma trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wennergren-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilken_x002d_Jensen-1975">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wilson-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>not an asthma trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolfe-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolthers-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>letter</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wong-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 15 days inh steroid, length not an outcome</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wyatt-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>not a clinical trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yazigi-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>only 1 day inhaled steroid</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Doull-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Simons-1997">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Verberne-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Inhaled Steroid vs placebo</NAME>
<CONT_OUTCOME CHI2="2.71417965937317" CI_END="1.936275659645117" CI_START="1.1525178700172227" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="1.5443967648311698" ESTIMABLE="YES" I2="26.312910308159452" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.2574090002382853" P_Q="1.0" P_Z="1.1253302333720296E-14" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="145" TOTAL_2="128" UNITS="" WEIGHT="100.0" Z="7.724228267884608">
<NAME>Linear growth velocity</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="1.8075107712166352" CI_START="0.35248922878336497" EFFECT_SIZE="1.08" ESTIMABLE="YES" MEAN_1="-3.96" MEAN_2="-5.04" ORDER="1" SD_1="2.04" SD_2="2.04" SE="0.37118578553236037" STUDY_ID="STD-Simons-1997" TOTAL_1="67" TOTAL_2="55" WEIGHT="29.015154922966055"/>
<CONT_DATA CI_END="2.4291996979780897" CI_START="0.3708003020219093" EFFECT_SIZE="1.3999999999999995" ESTIMABLE="YES" MEAN_1="-4.7" MEAN_2="-6.1" ORDER="2" SD_1="1.87" SD_2="2.04" SE="0.5251115357712112" STUDY_ID="STD-Verberne-1997" TOTAL_1="32" TOTAL_2="25" WEIGHT="14.49787827116223"/>
<CONT_DATA CI_END="2.3414080681963467" CI_START="1.2985919318036538" EFFECT_SIZE="1.8200000000000003" ESTIMABLE="YES" MEAN_1="-4.12" MEAN_2="-5.94" ORDER="3" SD_1="1.41" SD_2="1.15" SE="0.2660294129428636" STUDY_ID="STD-Doull-1995" TOTAL_1="46" TOTAL_2="48" WEIGHT="56.4869668058717"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK MODIFIED="2011-07-08 09:21:45 +0100" MODIFIED_BY="Emma J Welsh">
<FEEDBACK_ITEM ID="FBK-01" MODIFIED="2011-07-08 09:21:45 +0100" MODIFIED_BY="Emma J Welsh" NO="1">
<TITLE MODIFIED="2011-05-25 16:21:08 +0100" MODIFIED_BY="Emma J Welsh">An alternate evaluation of evidence: results from a CASP workshop</TITLE>
<DATE_SUBMITTED>
<DATE DAY="29" MONTH="4" YEAR="2011"/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY MODIFIED="2011-07-08 09:21:45 +0100" MODIFIED_BY="Emma J Welsh">
<P>In 2010 paediatric hospital professionals attending an EBM workshop held in Rome critically appraised this systematic review (SR). To do so they compared the acknowledged Critical Appraisal Skill Programme (CASP) tool with an unpublished strategy developed in Ulm University, Evidence-Based Knowledge Brokering (EBKB), appraising only the two weighted RCTs in the forest plot.</P>
<P>When participants used the CASP, they found good internal validity (clear research question, detailed search strategy, right studies included, appropriate assessment and statistical analysis). Answering the question on external validity, participants could not tell whether the results applied to the local population, especially given baseline differences in pre-study inhaled corticosteroid treatment (from no prior steroid treatment permitted, to stipulating a pre-treatment exposure of 3 months before the study). Even though the Cochrane review authors suggested these differences had scarce influence on outcome, given similar effect sizes and low heterogeneity (I<SUP>2</SUP> = 26%), workshop participants were sceptical about differences in asthma severity and brief follow-up.</P>
<P>With the EBKB strategy, despite a clearly stated research question, workshop<B> </B>participants identified major limitations rating internal validity as poor. For example, they identified possible publication bias with the exclusion of long-term prospective studies needed to answer the research question (Sinha et al. 2008). The authors also neglected possible risk distribution from age-related changes including children 6 to 16 years, the typical age for constitutional growth delay, overweight children and children in different pubertal stages at baseline (selection bias). Because severity scores for asthmatic children were assessed differently in the two RCT studies, workshop participants suspected a type I error, and attrition bias from the numerous patients lost to follow-up. Participants also questioned including the study by Simons et al. because allocation concealment was unclear and the review authors did not contact the authors to clarify this. Appraising the longitudinal study by Doull et al., workshop participants considered the research question clear, but in excluding children using oral or inhaled corticosteroids the investigators failed to specify other possible routes and timing. Furthermore the review authors did not specify whether this population had received corticosteroids in before study-entry. Despite saying why Doull et al. excluded 10 children, the review authors considered all 94 children but did not provide an intention-to-treat analysis. Our participants suspected that removing the data for 6 children at a mean age of 8.5 years (pubertal development, inhaled corticosteroids, back injury) might have introduced selection bias from adverse events, for example iatrogenic precocious puberty, attributable to unspecified systemic corticosteroid therapy (Leone et al 2003; Leong et al 2007). Nor did the study provide information on overweight, children&#8217;s bone age (Epstein et al. 1985; Preece 1988; Spadoni and Cianfarani 2010), and bone turnover (Baxter-Jones 2002). Given the similar adrenal function test findings (urinary cortisol) in Doull et al.&#8217;s study, participants suspected that the significant result in the linear growth regression analysis (SD 2.66 versus 3.66 cm CI -1.36 to -0.64) was a possible type I error.</P>
<P>Using the EBKB strategy, workshop participants also appraised Verberne et al.&#8217;s study. Because corticosteroid-related changes in height were considered only as a secondary outcome (adverse events), although the population included pubertal children (6 to 16 years), no information was provided on baseline characteristics for pubertal development, bone age and pubertal stages (clinical/x-ray/hormonal tests). Hence participants suspected that the significant linear growth decrease might be a transient effect ultimately followed by catch-up growth (Lipworth 1999). In assessing external validity, participants concluded that these shortcomings prevented them from generalising the findings to the local population.</P>
<P> In conclusion, the new EBKB appraisal strategy provides useful feedback that might help the review authors to reconsider their recommendations, elucidate uncertainty around corticosteroid doses and update this SR of intense interest to health professionals caring for children with asthma.</P>
<TABLE COLS="1" ROWS="1">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Summary of the evidence-based knowledge brokering (EBKB) strategy used for appraising systematic reviews (SRs)</B>
</P>
<P>
<B> </B>
</P>
<P>
<B>First step </B>Check whether the research question in the last paragraph in the introduction is clearly stated. If yes, complete the following five steps; if no, suspect poor internal validity.</P>
<P>
<B>Second step</B> Check which method you consider simple and appropriate for answering the stated research question.</P>
<P>
<B>Third step</B> Identify two or more major randomised controlled trials (RCTs) (high weight in the SR forest plot)</P>
<P>
<B>Fourth step</B> Read the methods section. Read details of the two RCT populations (Table 1 in the RCT) and say whether you consider<B> </B>the population and study setting appropriate for comparison with the control group, for example similar risk profiles, and patients&#8217; demographic characteristics.</P>
<P>
<B>Fifth step</B> Say whether you consider the statistical tests adequate for answering the question, for example, whether the study group and control group had the same risk distribution.</P>
<P>
<B>Final step</B>
</P>
<P>Express finally an opinion on whether the answer to the research question was clinically relevant and whether the study is valid to be included in the SR.</P>
</TD>
</TR>
</TABLE>
<P/>
<P>
<B>REFERENCES</B>
</P>
<P>Baxter-Jones A D G, Helms P J. Early introduction of inhaled steroids in wheezing children presenting in primary care: a pilot study. <I>Clin Exp Allergy</I> 2000; <B>30</B>(11):1618-1626.</P>
<P>Epstein LH, Wing RR, Valoski A. Childhood obesity. <I>Pediatr Clin North Am</I>. 1985 Apr;<B>32</B>(2):363-79.</P>
<P>Leone FT, Fish JE, Szefler SJ, West SL Systematic review of the evidence regarding potential complications of inhaled corticosteroid use in asthma: collaboration of American College of Chest Physicians, American Academy of Allergy, Asthma, and Immunology, and American College of Allergy, Asthma, and Immunology. <I>Chest</I> 2003;<B>124</B>;2329-2340.</P>
<P>Leong GM, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Abad%20V%22%5BAuthor%5D">Abad V</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Charmandari%20E%22%5BAuthor%5D">Charmandari E</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reynolds%20JC%22%5BAuthor%5D">Reynolds JC</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hill%20S%22%5BAuthor%5D">Hill S</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Chrousos%20GP%22%5BAuthor%5D">Chrousos GP</A>, <A HREF="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nieman%20LK%22%5BAuthor%5D">Nieman LK</A>. Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. <I>J Bone Miner Res</I> 2007 Jan;<B>22</B>(1):110-8.</P>
<P>Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. <I>Arch Intern Med</I> 1999;<B>159(</B>9):941-955. </P>
<P>Preece MA. Prediction of adult height: methods and problems. <I>Acta Paediatr Scand</I> Suppl. 1988;<B>347:</B>4-11.</P>
<P>Sinha I, Williamson PR, Smyth RL. Outcomes in clinical trials of inhaled corticosteroids for children with asthma are narrowly focused on short term disease activity. PLoS ONE <B>4</B> (7):e6276. DOI: 10.1371/journal.pone.0006276.</P>
<P>Spadoni GL, Cianfarani S. Bone age assessment in the work up of children with endocrine disorders. <I>Horm Res Paediatr</I> 2010;73(1):2-5<I> </I>
</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY MODIFIED="2011-05-27 16:59:23 +0100" MODIFIED_BY="Emma J Welsh">
<P>This review is no longer being updated. It is being replaced by three new protocols evaluating the effect of inhaled steroids on growth. The unabridged version of this feedback has been sent to the authors of the new protocols.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS MODIFIED="2011-05-25 16:09:40 +0100" MODIFIED_BY="Emma J Welsh">
<P>G.A.L.I.L.E.O. Gruppo per l&#8217;Apprezzamento della Letteratura e l&#8217;Implementazione dei Livelli di Evidenza in Ospedale.</P>
<P>Paola Rosati, Paolo Ciampalini, Armando Grossi, Luigi Giovannelli, Ferruccio Giustini, Rita Inglese, Ersilia Fiscarelli, Chiara Castellano§, Mercedes Rita Marina Mazziotta, Simonetta Gentile, Rosaria Giampaolo, Franz Porzsolt*.</P>
<P>Bambino Gesù Ospedale Pediatrico Rome, Italy</P>
<P>§ Facoltà di Medicina e Chirurgia , Scuola di Specializzazione in Pediatria Sapienza Università Rome, Italy</P>
<P>*Clinical Economics, University Ulm, Germany</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>